| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Lipocine Inc.$2.14
+0.06 (+2.88%)
C 48Pipeline Score Undervalued Pharma · Clinical
Market Cap
18.63 M
EPS
-1.96
P/E Ratio
-
Value Trade
132.19 K
SEC Financials
Q1 2026Dilution Risk
Revenue
119.40 K
R&D Expenses
2.76 M
Operating CF
-2.26 M
Total Assets
25.36 M
Total Liabilities
2.53 M
Equity
22.83 M
D/E Ratio
12,345
-1.31 %
Week
-3.42 %
1 Month
-75.59 %
3 Month
-28.48 %
6 Month
-90.51 %
5 Year
-99.34 %
All Time
Cash Data
Cash Position
24.73 M
Monthly Burn
752.00 K
Runway
30.2 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
29.43 K
52 Week Range
1.81 - 12.37
% held by Insiders
4.53 %
% held by Institutions
37.83 %
Enterprise Value
-6.10 M
Total Shares
5.55 M
Short %
2.37 %
Float Shares
5.19 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lipocine Inc.
898Total events
3Upcoming
287Tier-1 (high impact)
2013 – 2026Coverage
Upcoming catalysts 2
TBD
T2Oral Presentation
Subscribe to view catalyst details
TBD
T1Breakthrough Therapy Designation
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
●NDA SubmissionRegulatory Filing
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | LPCN 1154 | Phase 3 data readout | Phase 3 | — | – | – | – |
2026-06-30 | LPCN 1154 | Phase 3 data readout | Phase 3 | — | – | – | – |
2026-06-30 | LPCN 1154 | Phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
C48
Pipeline Score $88M
Pipeline ValueUndervalued
Valuation Signal6
Drugs Scored4.8x
rNPV / MCap Top 75%
Micro Cap (rank 229 of 913)
Percentile RankLipocine Inc. carries a moderate pipeline score (48/100), with $1.8B risk-adjusted pipeline value, led by testosterone undecanoate, LPCN 1021 in Male Hypogonadism (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| testosterone undecanoate, LPCN 1021 Small molecule | Male Hypogonadism | Phase 3 | NCT02081300 | 54% | $452M | COMPLETED | 315 | - | - | May 1, 2015 | - | Oct 23, 2017 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LPCN 1154 Fast Track | Postpartum Depression | Phase 3 | 2026-05-07 | N=90; no treatment-related serious adverse events; no cases of excessive sedation or loss of consciousness; no treatment-related discontinuations; n=54 Read More | Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 Read More | |
LPCN 1154 Fast Track | Postpartum Depression | Phase 3 | 2026-05-07 | N=90; no treatment-related serious adverse events; no cases of excessive sedation or loss of consciousness; no treatment-related discontinuations; n=54 Read More | Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 Read More | |
LPCN 1154 Fast Track | Postpartum Depression | Phase 3 | 2026-05-07 | N=90; no treatment-related serious adverse events; no cases of excessive sedation or loss of consciousness; no treatment-related discontinuations; n=54 Read More | Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LPCN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LPCN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LPCNLipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Lipocine Inc. announced a virtual Key Opinion Leader (KOL) event focusing on postpartum depression (PPD) and its investigational oral treatment, LPCN 1154. Scheduled for June 12, 2026, the webinar will feature expert discussions on PPD's unmet clinical needs and the latest results from Phase 3 trials of LPCN 1154, which aims to provide convenient at-home treatment. The event aims to engage leading physicians and will include a Q&A session for attendees.
Read more →LPCNLipocine to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 Live webinar to take place on Friday
Lipocine Inc. is hosting a virtual Key Opinion Leader event on June 12, 2026, to discuss ongoing unmet needs in postpartum depression (PPD) and the clinical profile of LPCN 1154, an investigational oral formulation of brexanolone. The webinar will bring together leading physicians to review the current treatment landscape, persistent gaps in care, and present Phase 3 trial results for LPCN 1154. Attendees will explore the potential impact of LPCN 1154 within the PPD treatment paradigm. Advance registration for the event is required and a replay will be available afterward.
Read more →LPCNAnaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
Anaveon has appointed Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer. These appointments aim to enhance the company's leadership and accelerate its clinical development and pipeline expansion in the field of autoimmune and inflammatory diseases. Both executives bring extensive experience in their respective fields, which is expected to drive Anaveon's growth and impact.
Read more →LPCNLipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
Lipocine Inc. announced that its Phase 3 clinical data for LPCN 1154 has been accepted for an oral presentation at the 2026 ASCP Annual Meeting. The presentation will focus on LPCN 1154's efficacy in treating postpartum depression. The company highlights the potential of LPCN 1154 to provide rapid symptom relief with minimal side effects.
Read more →LPCNLipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
Lipocine Inc. will participate in A.G.P.'s Annual Healthcare Company Showcase on May 20, 2026. The event will feature a fireside chat with management, highlighting Lipocine's innovative oral delivery technology and its drug development pipeline. The company aims to address significant unmet medical needs with its diverse range of drug candidates.
Read more →LPCNLipocine Inc. Lipocine Announces Financial Results for the First Quarter Ended
Lipocine Inc. announced its financial results for the first quarter ended March 31, 2026, reporting a net loss of $3.7 million, an increase from the previous year's loss. The company disclosed that LPCN 1154, under investigation for treating postpartum depression, failed to meet its primary endpoint in a Phase 3 study, despite showing some positive results in a subgroup analysis. Lipocine is currently contemplating its development strategy for LPCN 1154 and has applied for breakthrough therapy and fast track designations with the FDA. The company's cash reserves have grown significantly, providing a stronger financial foundation for future development efforts.
Read more →LPCNLipocine Announces Financial Results for the First Quarter Ended March 31, 2026
Lipocine Inc. reported its financial results for Q1 2026, highlighting the Phase 3 trial results for LPCN 1154, which did not meet its primary endpoint for treating postpartum depression. However, the drug was well tolerated, and significant improvements were noted in a subset of patients. The company is exploring further development options and has applied for breakthrough therapy designation.
Read more →LPCN▼ -5.4%on this news
Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating Lipocine Inc. (NASDAQ: LPCN) due to potential claims from investors following disappointing results from the company's LPCN 1154 Phase 3 trial for postpartum depression. The trial failed to demonstrate a statistically significant reduction in HAM-D17 total scores, leading to a decline in stock price. Investors who incurred losses are encouraged to seek information from the law firm about their rights and potential recovery options. The investigation hinges on whether Lipocine's executives complied with federal securities laws during the trial announcement.
Read more →LPCN▼ -77.8%on this newsshared move
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
Lipocine Inc. announced topline results from its Phase 3 trial of LPCN 1154 for postpartum depression. The trial did not meet its primary endpoint, showing no significant reduction in HAM-D scores compared to placebo. However, LPCN 1154 was well tolerated, with no serious adverse events reported. The company is exploring further development options and has applied for breakthrough therapy designation.
Read more →LPCNLipocine Announces Financial Results for the Full Year Ended
Lipocine Inc. announced its financial results for the full year ended December 31, 2025, highlighting a pivotal year for the company. Their revenue fell significantly to $2.0 million from $11.2 million in the previous year, leading to a net loss of $9.6 million. Despite these challenges, Lipocine remains optimistic about its drug developments, particularly its LPCN 1154 therapy for postpartum depression. Furthermore, the company's cash reserves increased to approximately $24.7 million as of March 2026.
Read more →LPCNLipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Lipocine Inc. has announced that the last patient completed their final visit in the pivotal Phase 3 trial of LPCN 1154, designed to treat postpartum depression. The trial involved 90 patients and reported a positive safety profile, with no serious side effects noted. The drug's oral formulation aims to provide rapid relief for new mothers suffering from severe postpartum depression, addressing significant existing gaps in treatment options. Data from this trial will support a 505(b)(2) NDA submission expected in 2026.
Read more →LPCN▼ -10.9%on this news
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Inc. has completed enrollment and dosing in its Phase 3 trial for LPCN 1154, an oral treatment for postpartum depression (PPD). The trial involved 90 patients and has shown a favorable safety profile with no serious adverse events reported. Results are anticipated in early Q2 2026, which may support a future NDA submission.
Read more →LPCN▲ +12.7%on this news· ran to +41% by day 3
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Company on track to report topline results early in the second quarter of 2026 Second p
Lipocine Inc. announced positive updates from the second interim safety review of its Phase 3 trial for LPCN 1154, an oral formulation aimed at treating postpartum depression (PPD). The independent Data Safety Monitoring Board (DSMB) recommended the trial continue without modifications, reporting no serious adverse events among the participants. With ongoing enrollment and a successful safety profile, Lipocine is set to release topline results in the second quarter of 2026, potentially paving the way for a new treatment option in PPD. The company aims to file a New Drug Application based on the trial data in 2026.
Read more →LPCNLipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Lipocine Inc. has announced that its Phase 3 clinical trial for LPCN 1154, aimed at treating postpartum depression (PPD), has reached 80% enrollment. The trial, which has received positive feedback from the FDA, is being conducted entirely in an outpatient setting. The results are expected to support a 505(b)(2) NDA submission in 2026.
Read more →LPCN▲ +12.7%on this news
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Inc. has reported positive interim results from its Phase 3 trial of LPCN 1154 for postpartum depression. An independent Data Safety Monitoring Board review confirmed no serious adverse events and recommended the trial continue as planned. The trial aims to evaluate LPCN 1154's safety and efficacy in women diagnosed with severe postpartum depression, with results expected in 2026.
Read more →LPCNLipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
Lipocine Inc. announced its financial results for Q3 2025, reporting a net loss of $3.2 million, an increase from the previous year's loss. The company had $15.1 million in cash reserves, down from $21.6 million at the end of 2024. Despite the losses, Lipocine generated royalty revenue from TLANDO sales, marking a positive development. The company continues to advance its clinical trials for various drug candidates.
Read more →LPCNLipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
Lipocine Inc. presented promising data on LPCN 2401 at ObesityWeek, highlighting its rapid effectiveness in improving body composition and liver health in men with obesity. The Phase 2 trial data indicates significant benefits in lean mass preservation and fat reduction. LPCN 2401 may also enhance the effects of other obesity treatments, although risks related to clinical development remain.
Read more →LPCNLipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) One-Third of Patients Randomized; Topline Results Expected in 2Q 2026 DSMB Safety Review Update Planned for 4Q 2025
Lipocine Inc. has provided an update on its Phase 3 clinical trial for LPCN 1154, an oral formulation aimed at treating postpartum depression. Currently, one-third of the planned patients have been randomized, with topline results expected in the second quarter of 2026. An independent Data Safety Monitoring Board will review safety data and provide an update by the fourth quarter of 2025. The company remains optimistic about the treatment's potential to meet significant needs in postpartum depression management.
Read more →LPCNLipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
Lipocine Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The company is focused on innovative oral delivery systems and has several drug candidates in development for various conditions, including postpartum depression and epilepsy. Investors can register for the conference and arrange meetings with Lipocine management.
Read more →LPCNLipocine to Present at H.C. Wainwright 27 th Annual Global Investment Conference
Lipocine Inc. (NASDAQ: LPCN) will present at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025. The company aims to showcase its proprietary technology in developing oral delivery products and engage with investors. Lipocine has several drug candidates under development, including LPCN 1154 for postpartum depression and LPCN 2101 for epilepsy, among others. The conference offers an opportunity for Lipocine to explore potential partnerships and investment opportunities.
Read more →LPCNLipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
Lipocine Inc. announced that two abstracts related to LPCN 2101 have been accepted for poster presentation at the 2025 American Epilepsy Society annual meeting. The abstracts focus on the pharmacokinetics and tolerability of LPCN 2101, which is being developed as a treatment for epilepsy. The meeting will take place from December 5-9, 2025, in Atlanta, Georgia.
Read more →LPCNLipocine Announces Financial Results for the Second Quarter Ended
Lipocine Inc. announced its financial results for the second quarter ended June 30, 2025, highlighting progress in its clinical studies. The company began treating patients in a pivotal Phase 3 trial for LPCN 1154, aimed at addressing postpartum depression. Moreover, Lipocine plans to initiate a Phase 2 study for LPCN 2401 for obesity treatment. Despite some advances, Lipocine reported a net loss and a decrease in cash reserves compared to the previous year.
Read more →LPCNLipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression Phase 3 Top Line Results Expected Q2 2026
Lipocine Inc. has announced the dosing of the first patient in its Phase 3 clinical trial for LPCN 1154, an oral treatment aimed at addressing postpartum depression. The trial will evaluate the efficacy of LPCN 1154 in women aged 15 and older compared to a placebo, with initial results expected in Q2 2026. This study aims to support a New Drug Application (NDA) submission, as the company addresses an important unmet need for rapid relief in postpartum depression. The treatment, which features a dosing period of 48 hours, leverages the mechanisms of naturally occurring neuroactive steroids.
Read more →LPCNLipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
Lipocine Inc. will host a virtual R&D investor event on July 9, 2025, to discuss LPCN 1154, a potential treatment for postpartum depression. The event will feature Dr. Kristina M. Deligiannidis and will cover the treatment landscape, unmet needs, and updates on a Phase 3 study. LPCN 1154 aims to provide rapid relief for postpartum depression symptoms.
Read more →LPCN▲ +6.3%on this news
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
Lipocine Inc. announced that its partner, Verity Pharma, has filed a New Drug Submission for TLANDO in Canada. TLANDO is the first oral testosterone replacement therapy approved by the FDA that does not require dose titration. The Canadian market, with over 700,000 TRT prescriptions annually, represents a significant opportunity for TLANDO's introduction. If approved, it could lead to substantial market gains.
Read more →LPCNLipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
Lipocine Inc. announced that its candidate LPCN 1148 is featured in the Hepatology Highlights of the June 2025 edition of Hepatology, emphasizing its potential for treating cirrhosis. The publication includes analyses from a Phase 2 trial, with promising outcomes that demonstrate LPCN 1148's efficacy. The candidate has also received fast track designation from the US FDA, highlighting its importance in managing sarcopenia in cirrhotic patients. CEO Mahesh Patel noted that this recognition reflects LPCN 1148's potential to improve patient outcomes in a disease with significant unmet medical needs.
Read more →LPCN▲ +10.1%on this news· ran to +30% by day 1
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
Lipocine Inc. (NASDAQ: LPCN) announced its participation in A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025. This virtual event will spotlight the company's proprietary technology aimed at effective oral delivery of therapeutics. Lipocine is developing several drug candidates targeting various conditions, including postpartum depression and obesity management. The presentation will be accessible via a webcast link provided by the company, reinforcing its commitment to engaging with investors and stakeholders.
Read more →LPCNLipocine Announces Financial Results for the First Quarter Ended
Lipocine Inc. announced its financial results for the first quarter of 2025, showing a net loss of $1.9 million and a decrease in cash reserves. The company has initiated a Phase 3 safety and efficacy study for LPCN 1154, targeting postpartum depression, with expected patient dosing in Q2 2025. Additionally, Lipocine is pursuing partnerships for LPCN 1154 and LPCN 2401, which is aimed at obesity management. The financial report highlights lower royalty revenues from TLANDO sales compared to the prior year.
Read more →LPCNLipocine Announces License and Supply Agreement for TLANDO in Brazil
Lipocine Inc. has entered a license and supply agreement with Ach Laboratórios Farmacêuticos S.A. to exclusively market TLANDO, an oral testosterone replacement therapy, in Brazil. This agreement comes at a time when the Brazilian market for testosterone products is expanding, with a significant compound annual growth rate. Ach will handle regulatory submissions and approvals, while Lipocine received an upfront payment and potential royalties. This agreement marks a strategic growth opportunity for Lipocine in a new market.
Read more →LPCNLipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 48 hour at-home dosing Patient dosing expected in Q2/2025
Lipocine Inc. has initiated a Phase 3 trial for LPCN 1154, an oral formulation of brexanolone, targeting the treatment of postpartum depression (PPD). The trial, which is randomized and placebo-controlled, aims to evaluate the safety and efficacy of LPCN 1154 in women aged 15 years and older diagnosed with severe PPD. Patient dosing is expected to commence in the second quarter of 2025, with the study designed to support global registration. LPCN 1154 is positioned as a potentially rapid relief option for PPD sufferers.
Read more →LPCNLipocine Announces FDA Labeling Changes for Testosterone Products
Lipocine Inc. announced FDA labeling changes for approved testosterone products, following the TRAVERSE clinical trial findings. The FDA has lifted the Boxed Warning regarding cardiovascular risks, recommending new product-specific information and retention of limits for age-related hypogonadism. This regulatory update is expected to enhance the marketability of Lipocine's testosterone replacement therapy, which is promoted under a partnership with Verity Pharma. Lipocine is also developing additional product candidates targeting various medical conditions, leveraging its proprietary oral delivery technology.
Read more →LPCN▼ -14.7%on this news
Lipocine Receives Updated Regulatory Guidance on LPCN 1154
Lipocine Inc. has announced that it received updated regulatory guidance from the FDA regarding its LPCN 1154 program aimed at treating postpartum depression. Following a recent meeting, the FDA indicated that, in addition to existing pharmacokinetic bridge data, a safety and efficacy study involving LPCN 1154 is necessary for the NDA submission. The company is proceeding with plans for a Phase 3 study, focusing on generating safety data that may aid in product labeling. Additionally, the inquiry into the use of LPCN 1154 for treating anxiety disorders has been proposed as a supplementary opportunity.
Read more →LPCNFDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
Lipocine Inc. announced that the FDA has granted Fast Track Designation to its drug LPCN 1148, aimed at treating sarcopenia in patients with decompensated cirrhosis. This designation is an acknowledgment of the drug's potential in addressing a serious condition with no current therapeutic options. LPCN 1148, which is an oral prodrug that has shown promise in a Phase 2 proof-of-concept study, is positioned as a potential first-in-class treatment with a novel mechanism of action. The Fast Track program will facilitate the expedited development and review process for LPCN 1148, reflecting its significance in improving patient outcomes.
Read more →LPCNLipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
Lipocine Inc. announced the publication of their LPCN 1148 manuscript, which discusses its effects on sarcopenia and overt hepatic encephalopathy in male patients with cirrhosis. The study, featured in Hepatology, reports significant improvements over placebo in both indications following a Phase 2 trial. Notably, LPCN 1148 appears to reduce episodes of hepatic encephalopathy, marking it as a potential first-in-class treatment. Insights from this research were shared during The Liver Meeting's Editor's Cut Session, emphasizing its relevance in addressing unmet medical needs in liver disease management.
Read more →LPCN▼ -7.8%on this news· ran to -21% by day 1
Lipocine Announces Financial Results for the Third Quarter Ended
Lipocine Inc. announced its financial results for the third quarter ending September 30, 2024, reporting a net loss of $2.2 million. The company highlighted positive developments in its clinical trials, including promising qEEG study results for LPCN 1154, an oral treatment for postpartum depression. Furthermore, LPCN 2401 demonstrated potential benefits for obesity management, as evidenced by positive Phase 2 study outcomes. While net losses have decreased compared to the previous year, the company did not generate any revenue during the quarter.
Read more →LPCNLipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO in South Korea
Lipocine Inc. has entered into a distribution and license agreement with SPC Korea for the commercialization of TLANDO, its testosterone replacement therapy, in South Korea. The agreement grants exclusive marketing rights to SPC Korea, and includes upfront, regulatory, and sales milestone payments for Lipocine. This partnership aims to meet the significant medical needs in the region and represents a strategic move to broaden TLANDO's global reach. Lipocine continues to explore various opportunities in its product development pipeline.
Read more →LPCNLipocine Announces Positive Oral Brexanolone Quantitative EEG Results
Lipocine Inc. announced positive results from a Quantitative Electroencephalogram (qEEG) study of oral brexanolone, indicating effective GABA A modulation and robust CNS activity. The study, involving healthy postmenopausal females, demonstrated significant changes in brain wave patterns post-dose, supporting the drug's potential for treating neuropsychiatric conditions. The favorable safety profile further encourages ongoing development.
Read more →LPCNLipocine Announces Positive Oral Brexanolone Quantitative EEG Results Quantitative Electroencephalogram (qEEG) in healthy subjects administered single doses of oral brexanolone, a neuroactive steroid (NAS), confirmed GAB
Lipocine Inc. announced positive results from a quantitative EEG study of oral brexanolone, confirming its effective delivery and CNS target engagement. The study showed significant changes in spectral power linked to the modulation of GABAA, highlighting potential utility in treating neuropsychiatric disorders like postpartum depression. The safety profile of brexanolone was favorable, consistent with prior studies, reinforcing plans for continued clinical development.
Read more →LPCN▲ +6.2%on this newsshared move
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO in the Gulf Cooperation Council (GCC) Countries
Lipocine Inc. has announced an exclusive supply and distribution agreement with Pharmalink to commercialize its oral testosterone replacement therapy, TLANDO, in the Gulf Cooperation Council (GCC) countries, which include Saudi Arabia, Kuwait, the UAE, Qatar, Bahrain, and Oman. The agreement includes an upfront payment to Lipocine and establishes Pharmalink as the exclusive distributor responsible for promoting and selling TLANDO in the region. This partnership is expected to enhance the accessibility of TLANDO and support its adoption in these markets. The deal aligns with Lipocine's broader strategy to expand its product reach internationally.
Read more →LPCNLipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on
Lipocine Inc. has announced a virtual key opinion leader (KOL) event scheduled for October 16, 2024, where LPCN 2401 will be discussed. This event will highlight the Phase 2 study results of LPCN 2401, an oral anabolic androgen receptor agonist showing promise in improving body composition in obesity management. The presentation will include insights from Dr. Frank Greenway, focusing on current treatment options and unmet needs in obesity management. The company aims to explore the potential of LPCN 2401 as an adjunct therapy to existing treatments, such as incretin mimetics.
Read more →LPCNLipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference
Lipocine Inc. will present at the H.C. Wainwright 8th Annual MASH Investor Conference on October 7, 2024. The event will be held virtually, and Lipocine intends to meet with investors during this opportunity. The company is focused on developing differentiated products with its proprietary technology platform for effective oral delivery. Among its clinical candidates are treatments for postpartum depression, epilepsy, and chronic weight management.
Read more →LPCNLipocine to Present at H.C. Wainwright 8 th Annual MASH Investor Conference
Lipocine Inc. (NASDAQ: LPCN) will present at the H.C. Wainwright 8th Annual MASH Investor Conference on October 7, 2024. The company aims to engage with investors about its proprietary technology in oral drug delivery and its various drug candidates. Lipocine has multiple products in development targeting conditions such as postpartum depression and epilepsy. However, the company also acknowledges the risks associated with product development and regulatory approval processes.
Read more →LPCNLipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
Lipocine Inc. announced that Phase 2 data on LPCN 2401 will be presented at the upcoming ObesityWeek conference. LPCN 2401 is an oral formulation designed to aid in weight management and improve body composition. The drug has shown promise in clinical studies for gaining lean mass while losing fat mass, particularly as an adjunct therapy to incretin mimetics.
Read more →LPCNLipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek Study evaluated LPCN 2401 in participants with obesity (BMI 30) and participants with BMI 27 with at least one weight-related comorbidity
Lipocine Inc. has announced that Phase 2 data on its product LPCN 2401 will be presented at the Obesity Society's Annual ObesityWeek conference from November 3-6, 2024. The study evaluates LPCN 2401's efficacy in participants with obesity and those with lower BMI but weight-related comorbidities. Preclinical and clinical studies suggest LPCN 2401 may aid in weight management by increasing lean mass while decreasing fat mass. Dr. Frank Greenway will present the findings on November 5, 2024.
Read more →LPCNLipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
Lipocine Inc. (NASDAQ: LPCN) is set to present at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024. Dr. Mahesh V. Patel, President and CEO, will discuss the company's technology platform and potential partnerships for various drug candidates. Lipocine's pipeline includes treatments for conditions such as postpartum depression, epilepsy, and chronic weight management. The conference will be accessible both in-person and virtually, providing opportunities for investors to engage with the company.
Read more →LPCN▼ -7.8%on this news· ran to -20% by day 3
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
Lipocine Inc. announced its financial results for Q2 2024, reporting a net loss of $3.1 million. The company highlighted positive study results for LPCN 1154, targeting NDA submission by the end of 2024. Additionally, LPCN 2401 demonstrated significant benefits for chronic weight management. The company continues to explore partnerships for its pipeline candidates.
Read more →LPCNLipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Lipocine Inc. has completed dosing in its pivotal study for LPCN 1154, a candidate for treating postpartum depression. The study design has been aligned with the FDA, aiming for a streamlined pathway to NDA submission by 2024. Topline results are anticipated in late Q2 2024, marking a significant step for the company.
Read more →LPCN▼ -12.4%on this news
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
Lipocine Inc. announced positive results for LPCN 1154, an oral formulation of brexanolone, demonstrating bioequivalence with IV brexanolone in a pivotal study. The study met the U.S. FDA's bioequivalence criteria, and LPCN 1154 was well tolerated with no sedation or somnolence observed. The company is on track to file a New Drug Application (NDA) by the end of Q4 2024, potentially introducing a new treatment option for postpartum depression. The findings highlight LPCN 1154's promising profile as an effective, fast-acting oral treatment for patients suffering from this serious condition.
Read more →LPCN▲ +6.1%on this news
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
Lipocine Inc. showcased the Phase 2 study results for LPCN 1148 during a late-breaking session at the EASL Congress 2024, held in Milan, Italy. The clinical trial focused on patients with cirrhosis and aimed to evaluate the treatment’s impact on issues such as sarcopenia and hepatic encephalopathy. This study is significant given the high prevalence of these complications in cirrhosis patients and the limited treatment options available. The findings may indicate progress in improving patient outcomes and addressing unmet medical needs in liver disease management.
Read more →LPCNLipocine Announces Financial Results for the First Quarter Ended March 31, 2024
Lipocine Inc. has announced its financial results for Q1 2024, highlighting growth and ongoing developments in its product pipeline. The company is focusing on LPCN 1154 for postpartum treatment and has secured a distribution agreement for TLANDO® in the GCC. Additionally, Lipocine is preparing for a virtual event to discuss LPCN 2401's role in obesity management.
Read more →LPCNLipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
Lipocine Inc. has announced a late-breaking oral presentation for data from its Phase 2 study of LPCN 1148, set to take place at the EASL Congress 2024 in Milan. The study focuses on LPCN 1148's effects on sarcopenia and hepatic encephalopathy in patients with cirrhosis. The company aims to address unmet medical needs and improve outcomes for patients. The presentation will be led by Dr. Arun J. Sanyal and is scheduled for June 8, 2024.
Read more →LPCNLipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024 Topline results anticipat
Lipocine Inc. has completed dosing in the pivotal pharmacokinetic study for LPCN 1154, an oral treatment for postpartum depression. The company has confirmed its alignment with the FDA on a streamlined pathway for a New Drug Application (NDA), targeting submission by the end of 2024. Topline results from the study are expected by late second quarter of 2024, which could address a significant unmet need in the treatment of postpartum depression. The market for postpartum depression is larger than previously estimated, affecting approximately 500,000 women annually in the U.S.
Read more →LPCNLipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increase
Lipocine Inc. announced positive results from a Phase 2 clinical trial for LPCN 2401, an oral treatment aimed at improving body composition in participants with obesity. The trial showed statistically significant results, including a 6.7% decrease in fat mass and a 4.4% increase in lean mass. LPCN 2401 was found to be well-tolerated, with adverse events reported at rates similar to placebo. There is an expectation for future discussions with the FDA regarding its further development as a weight management aid.
Read more →LPCNLipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study Increase in Skeletal Muscle Index (SMI) observed
Lipocine Inc. announced positive results from its Phase 2 study of LPCN 1148, an oral treatment for patients with cirrhosis. The study met its primary endpoint of increasing Skeletal Muscle Index (SMI), which was sustained over 52 weeks. Additionally, there were fewer cases of Overt Hepatic Encephalopathy (OHE) events reported among patients receiving LPCN 1148, leading to longer intervals before recurrent OHE. The positive findings suggest that LPCN 1148 could substantially benefit patients dealing with decompensated cirrhosis and sarcopenia.
Read more →LPCN▲ +8.9%on this news· ran to +29% by day 3shared move
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024
Lipocine Inc. has announced that the first cohort has been dosed in a pivotal pharmacokinetic study of LPCN 1154, an oral formulation aimed at treating postpartum depression (PPD). This study, which includes 24 healthy postmenopausal women, will evaluate the pharmacokinetics of LPCN 1154 compared to IV brexanolone. Topline results from this open-label, randomized trial are anticipated by late Q2 2024, aligning with plans to submit a New Drug Application by the end of Q4 2024. The company highlights a significant market need, as postpartum depression affects around 500,000 women annually in the U.S.
Read more →LPCNLipocine to Present at 36 th Annual Roth Conference
Lipocine Inc. will participate in the 36th Annual Roth Conference on March 18, 2024, where its President and CEO will engage in discussions with investors. The company focuses on delivering innovative treatments for Central Nervous System (CNS) disorders, with several drug candidates in development, including those for postpartum depression and epilepsy. While Lipocine is optimistic about its growth and product pipeline, it acknowledges various risks related to product development and regulatory approvals.
Read more →LPCNLipocine to Present at 36th Annual Roth Conference
Lipocine Inc. has announced that Dr. Mahesh V. Patel, President and CEO, will present at the 36th Annual Roth Conference in Laguna Niguel, CA, on March 18, 2024. The company aims to showcase its proprietary technology and drug candidates for Central Nervous System disorders, including LPCN 1154 for postpartum depression and LPCN 2101 for epilepsy. Lipocine seeks to engage with investors during the event and explore potential partnerships for its products. This event is expected to enhance the company's visibility within the biopharmaceutical sector.
Read more →LPCNLipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK study On track for Q2-24 pivotal study topline results an
Lipocine Inc. has confirmed the 48-hour dosing regimen for LPCN 1154 in its pivotal pharmacokinetic study, following positive results from a recent multi-dose clinical trial. The drug, aimed at treating postpartum depression, is set for NDA filing by the end of 2024, with topline results from the pivotal study expected in Q2-24. The results align with the FDA's acceptance of a proposal for a 505(b)(2) NDA filing, suggesting both optimistic data and regulatory support for the treatment.
Read more →LPCNLipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
Lipocine Inc. has announced that the commercialization of TLANDO, its testosterone replacement therapy, has been transferred to Verity Pharma as of February 1, 2024. This transition is aimed at ensuring ongoing patient access to TLANDO, which is unique as the first oral TRT option that does not require dose titration. Additionally, Lipocine received a significant portion of the license fee as part of its agreement with Verity Pharma and Gordon Silver Limited, which additionally outlines future payment timelines. However, the therapy does come with warnings regarding potential cardiovascular risks.
Read more →LPCNLipocine and Verity Pharma Enter into License Agreement for TLANDO Franchise in the U.S. and Canada Lipocine to receive $11 million license fee Up to $259 million in development and commercial sales milestones Tiered roy
Lipocine Inc. has entered a licensing agreement with Verity Pharma for the commercialization of TLANDO in the U.S. and Canada. Lipocine will receive an initial $2.5 million and could earn up to $259 million in future milestone payments. Verity Pharma will handle regulatory and marketing responsibilities while Lipocine retains rights outside North America. This agreement allows Lipocine to focus on its core CNS disorder treatments while expanding the TLANDO franchise.
Read more →LPCN▲ +11.4%on this news
Lipocine to Present at Biotech Showcase 2024
Lipocine Inc. (NASDAQ: LPCN) announced its participation in the Biotech Showcase 2024, scheduled for January 8-10, where the company will present and host meetings with institutional investors. The events will take place in San Francisco, California. Lipocine is focused on developing differentiated treatments for Central Nervous System disorders and has several drug candidates in various stages of development, including LPCN 1154 and LPCN 2101. Despite its innovative approach, the company faces risks related to product approvals and market acceptance.
Read more →LPCN▲ +11.4%on this news
Lipocine to Present at Biotech Showcase 2024 Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event
Lipocine Inc. (NASDAQ: LPCN) announced its participation in the Biotech Showcase 2024, where it will present its research and host meetings for investors on January 8-10, 2024, in San Francisco, California. The company focuses on developing therapeutics for Central Nervous System disorders and is exploring partnerships for its various drug candidates, including LPCN 1154 and LPCN 2101. The presence at this event indicates Lipocine's intention to enhance engagement with potential investors and partners. However, the company faces risks associated with FDA approvals and required capital for product development.
Read more →LPCN▲ +11.2%on this news
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting 2023 Results demonstrate improvements in sarcopenia and other clinically meaningful outcomes Patients converting from placebo
Lipocine Inc. has announced positive results from its Phase 2 study of LPCN 1148, showcasing improvements in sarcopenia and other clinically relevant outcomes among patients with cirrhosis. The findings were presented at The Liver Meeting 2023, emphasizing the potential of LPCN 1148 in addressing unmet needs in liver health management. An ongoing open-label extension will further assess the treatment's safety and efficacy. Future data release is anticipated in Q1 2024, which could provide more insights into the drug's overall benefits.
Read more →LPCNLipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting 2023 "Late Breaking" abstract scheduled for oral presentation on November 13
Lipocine Inc. announced that its abstract on LPCN 1148 has been selected for a late-breaking oral presentation at The Liver Meeting 2023. Scheduled for November 13, the presentation will discuss LPCN 1148's potential benefits in improving symptoms associated with cirrhosis, particularly sarcopenia and hepatic encephalopathy. This showcases Lipocine's commitment to addressing unmet medical needs in patients with advanced liver conditions. The session will be led by Dr. Arun J. Sanyal, an expert in liver disease.
Read more →LPCNLipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression Lipocine and FDA agreed on the acceptance criteria for the pivotal study which enables advancement of LPCN 1154 for postpartum depressi
Lipocine Inc. announced the successful completion of a meeting with the FDA regarding LPCN 1154, an oral treatment for postpartum depression. The FDA has agreed on the acceptance criteria for a pivotal study, which is set to begin in Q1 2024. This study aims to support a New Drug Application (NDA) filing based on LPCN 1154's performance compared to an existing treatment, IV brexanolone. Top-line results from the study are expected by Q2 2024, positioning LPCN 1154 as a potential rapid relief option for postpartum depression.
Read more →LPCNLipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
Lipocine Inc. announced its participation in the upcoming H.C. Wainwright 7th Annual NASH Investor Conference, scheduled for October 24, 2023. Dr. Benjamin Bruno, Senior Director of Clinical Development, will present Lipocine's portfolio, which includes drug candidates for postpartum depression, epilepsy, and liver cirrhosis. The company aims to leverage its proprietary technology for effective oral delivery and is exploring partnerships for its various candidates. However, potential risks concerning product development, regulatory approvals, and capital requirements are acknowledged in the announcement.
Read more →LPCNLipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
Lipocine Inc. will present at the 2023 Cantor Fitzgerald Global Healthcare Conference from September 26-28 in New York City. CEO Dr. Mahesh Patel will discuss the company's innovative approach to CNS disorders and its promising drug candidates, including LPCN 1154 for postpartum depression and LPCN 2101 for epilepsy. The presentation is expected to attract investor interest and could facilitate potential partnerships, reflecting Lipocine's commitment to developing effective treatments for unmet medical needs in the CNS space.
Read more →LPCN▲ +18.6%on this news
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P 0.01) Fewer hepatic encephalopat
Lipocine Inc. announced promising results from a Phase 2 study of LPCN 1148, an oral treatment for patients with cirrhosis. The study met its primary endpoint, showing a significant increase in the L3 skeletal muscle index compared to placebo. Patients receiving LPCN 1148 reported fewer incidents of hepatic encephalopathy and overall symptom improvement. The treatment was well-tolerated, and the company plans to engage with the FDA regarding the next steps towards filing a New Drug Application.
Read more →LPCNLipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference
Lipocine Inc. announced that its President and CEO, Dr. Mahesh Patel, will present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference on June 26, 2023. The conference will showcase Lipocine's advancements in treating Central Nervous System disorders through its proprietary platform. The company is actively exploring partnerships for its various CNS treatment candidates, including LPCN 1154 for postpartum depression and LPCN 2101 for epilepsy, among others. This opportunity aims to enhance Lipocine's engagement with investors and stakeholders in the biopharma industry.
Read more →LPCNLipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-202
Lipocine Inc. announced that its Phase 2 proof-of-concept study for LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled, with topline results expected by mid-2023. The company will present research findings for both LPCN 1148 and LPCN 1144 at the EASL Congress 2023 in Vienna. LPCN 1148 is designed to improve liver and muscle function, offering potential benefits during the wait for liver transplant. The presentations will provide further insights into the efficacy and safety of these treatments.
Read more →LPCN▼ -17.7%on this news
Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression Identified dosing regimen that enables reliance on a single confirmatory p
Lipocine Inc. announced positive topline results from a pilot clinical study of LPCN 1154, an oral candidate for the rapid relief of postpartum depression (PPD). The study found LPCN 1154 to be well-tolerated, with no serious adverse events reported. Lipocine plans to initiate a confirmatory pivotal pharmacokinetic study in the second half of 2023, which the FDA supports as a pathway for NDA submission. The promising results are seen as a significant step towards providing an effective treatment option for women suffering from PPD.
Read more →LPCNFirst Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154 LPCN 1154 is an oral formulation of brexanolone in development for the rapid relief of postpartum depression (PPD) Topline st
Lipocine Inc. announced that the first participant has been dosed in a pilot clinical bridge study for LPCN 1154, an oral formulation of brexanolone aimed at treating postpartum depression (PPD). This study is designed to compare the pharmacokinetics of LPCN 1154 to the approved injectable version. Positive results from this study could lead to a pivotal study and support for a New Drug Application (NDA). The FDA has agreed to this approach, indicating a favorable regulatory path for LPCN 1154.
Read more →LPCN▼ -26.8%on this news
Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock SALT LAKE CITY, MARCH 10, 2023 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on met
Lipocine Inc. has announced a pro rata distribution of Series B Preferred Stock to common stockholders, which will occur on March 24, 2023. Each holder of common stock will receive one one-thousandth of a share of the new preferred stock, which will have voting rights on specific corporate matters. Additionally, Lipocine continues to develop several product candidates for CNS disorders and is exploring partnerships for its therapeutic innovations, emphasizing market awareness and strategic growth potential. Despite these initiatives, the company faces typical risks associated with product development and regulatory approvals.
Read more →LPCN▼ -26.8%on this news
Lipocine Announces Financial Results for the Year Ended
Lipocine Inc. announced its financial results for 2022, reporting a significant increase in net loss to $10.8 million as compared to the previous year. The company is shifting its focus towards developing neuroactive steroids for Central Nervous System disorders and has made progress with its candidate LPCN 1154 for postpartum depression. Despite the financial challenges, Lipocine continues to explore partnerships and has initiated a pivotal study that could lead to an NDA filing.
Read more →LPCNLipocine to Present at Biotech Showcase Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event
Lipocine Inc. has announced its participation in the Biotech Showcase, where its management will present and hold meetings with investors from January 9-11, 2023, in San Francisco. The company focuses on treating Central Nervous System disorders and is showcasing its proprietary platform and clinical candidates, including treatments for postpartum depression and epilepsy. Additionally, Lipocine is exploring partnerships for certain developmental candidates. This event provides a platform for increasing visibility and potential collaboration opportunities in the biopharmaceutical space.
Read more →LPCNLipocine to Present at Biotech Showcase
Lipocine Inc. will present its developments at the Biotech Showcase and host investor meetings from January 9-11, 2023, in San Francisco, California. The company focuses on treating CNS disorders through a proprietary oral delivery technology. Their clinical candidates include LPCN 1154 for postpartum depression and LPCN 2101 for epilepsy. Additionally, Lipocine is considering partnerships for several of its products to address significant markets with unmet medical needs.
Read more →LPCN▲ +5.6%on this news
Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis Top-line 24-week results from proof-of-concept study expected mid-2023
Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis 24-week results from proof-of-concept study expected mid-2023 LAKE CITY, December 19, 2022 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS")
Read more →LPCNLipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline SALT LAKE CITY, November 3 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging
Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline LAKE CITY, November 3 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary platform to develop differentiated products, today anno
Read more →LPCNEFFICACY, SAFETY, AND TOLERABILITY OF CONTINUED LPCN 1144 TREATMENT IN NONALCOHOLIC STEATOHEPATITIS (NASH) SUBJECTS WITH FIBROSIS IN AN OPEN LABEL EXTENSION STUDY (OLE) Benjamin J Bruno 1 , Kongnara Papangkorn 1 , Anthon
SAFETY, AND TOLERABILITY OF CONTINUED LPCN 1144 TREATMENT IN NONALCOHOLIC STEATOHEPATITIS (NASH) SUBJECTS WITH FIBROSIS IN AN OPEN LABEL EXTENSION STUDY (OLE) J Bruno1, Kongnara Papangkorn1, Anthony DelConte1,2, Kilyoung Kim1, Nachiappan Chidambaram1, Mahesh V Patel1, Somaya A
Read more →LPCNLipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference
SALT LAKE CITY, Oct. 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules focused on trea
Read more →LPCN▼ -11.8%on this news
Lipocine to Participate in the Cantor Neurology & Psychiatric Conference
SALT LAKE CITY, Sept. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules focused on tre
Read more →LPCN▼ -10.4%on this news· ran to -21% by day 1shared move
Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders Company to apply its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products for Central Ner
Announces Strategic Realignment and Forward Focus on Treating CNS Disorders to apply its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders focus on oral delivery of neuroactive steroids
Read more →LPCNLipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference
SALT LAKE CITY, Sept. 22, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to augment therapeutics through effective oral delivery by developing differentiated products relative to standard of ca
Read more →LPCN▲ +5.7%on this news
Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) FDA agrees with Lipocine establishing LPCN 1154 pathway to efficacy through a pharmacokinetic (PK) bridge to an approved
Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) FDA agrees with Lipocine establishing LPCN 1154 pathway to efficacy through a pharmacokinetic (PK) bridge to an approved IV infusion brexanolone Lipocine has demonstrated that the brexa
Read more →LPCNFDA Clears LPCN 2101 IND for Adult Epilepsy Treatment Phase 2 Photosensitive Epilepsy Study Planned for 2H 2022
Clears LPCN 2101 IND for Adult Epilepsy Treatment 2 Photosensitive Epilepsy Study Planned for 2H 2022 LAKE CITY, July 11, 2022 /PRNewswire/ - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nerv
Read more →LPCNLIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS
SALT LAKE CITY, June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted US patent 11,337,987 for "Compositions
Read more →LPCNLIPOCINE
TO CNS AND LIVER PROGRAMS LAKE CITY, UT, June 14, 2022 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted US patent 11,337,987 for
Read more →LPCNLIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE
SALT LAKE CITY, June 6, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, presented "LPCN 2101: An Endogenous Neuroactive Steroid for Epilepsy" today at the 2022 Epi
Read more →LPCNLIPOCINE ANNOUNCES PRESENTATION AT 2022
ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE LAKE CITY, June 6, 2022 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, presented "LPCN 2101: An Endogenous N
Read more →LPCNLipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals Liver injury markers were reduced and maintained with exten
Announces Positive LPCN 1144 NASH Open Label LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals Liver injury markers were reduced and maintained with extended LPCN 1144 treatment Observed liver histology improvements support further developm
Read more →LPCNLIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS Industry veterans Jill M. Jene, Ph.D. and Spyros Papapetropoulos M.D. Ph.D. appointed to Board
ANNOUNCES BOARD of DIRECTOR APPOINTMENTS veterans Jill M. Jene, Ph.D. and Spyros Papapetropoulos M.D. Ph.D. LAKE CITY, April 11, 2022 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, announced today the appointment
Read more →LPCN▼ -20.3%on this news
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO Commercial launch expected in 2Q 2022
ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO launch expected in 2Q 2022 LAKE CITY, March 29, 2022 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, announced
Read more →LPCNLipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic
Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH LAKE CITY, March 1, 2022 -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today provided an update from the Type C guidance meeting wit
Read more →LPCNLIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO PDUFA target action date set for
ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO target action date set for March 28, 2022 LAKE CITY, February 3, 2022 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for metabolic
Read more →LPCNLipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for
Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO LAKE CITY, January 27, 2022 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the peer-reviewed publication of positive
Read more →LPCNLipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference
SALT LAKE CITY, Jan. 5, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that one abstract has been selected for podium presentation and three abstracts have been selected f
Read more →LPCNLIPOCINE ANNOUNCES patient dosed in its Phase 2 Study with LPCN 1148 for management of liver cirrhosis
ANNOUNCES patient dosed in its Phase 2 Study with LPCN 1148 for management of liver cirrhosis LAKE CITY, December 22, 2021 - Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first pat
Read more →LPCN▲ +6.3%on this news
Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic
Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH LAKE CITY, November 4, 2021 - Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug
Read more →LPCNLipocine Announces Multiple Poster Presentations At The American Association For The Study Of Liver Diseases (AASLD) The Liver Meeting 2021 Late Breaking Posters Will Feature Data From Phase 2 LiFT Study Investigating LP
Announces Multiple Poster Presentations At The American Association For The Study Of Liver Diseases (AASLD) The Liver Meeting 2021 Breaking Posters Will Feature Data From Phase 2 LiFT Study Investigating LPCN 1144 in NASH LAKE CITY, November 1, 2021 - Lipocine Inc. (NASDAQ: LPC
Read more →LPCNLipocine AND ANTARES PHARMA ENTER INTO U.S. Licensing Agreement to Commercialize TLANDO Under the terms of Agreement Lipocine to receive: Up to $21.0 million in licensing fees, including $11.0 million payable immediately
AND ANTARES PHARMA ENTER INTO U.S. Licensing Agreement to Commercialize TLANDO Under the terms of Agreement Lipocine to receive: Up to $21.0 million in licensing fees, including $11.0 million payable immediately and $10.0 million to be paid in the future subject to certain con
Read more →LPCNLipocine to Present at The H.C. Wainwright 5th Annual NASH Investor Conference
SALT LAKE CITY, Oct. 5, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the H.C. Wainwright 5th Annual NASH Investor Conference being held
Read more →LPCNLIPOCiNE ANNOUNCES FDA AFFIRMATION of class 1
ANNOUNCES FDA AFFIRMATION of class 1 NDA RESUBMISSION FOR TLANDO LAKE CITY, September 28, 2021 - Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the U.S. Food and Drug Administration ("FDA")
Read more →LPCNLipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®
SALT LAKE CITY, Sept. 28, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the U.S. Food and Drug Administration ("FDA") has affirmed the resubmission of its New Drug Applic
Read more →LPCNLipocine to Present at The Cantor Fitzgerald Virtual Global Healthcare Conference
SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Cantor Fitzgerald Virtual Global Healthcare Conference. The c
Read more →LPCNLipocine to Present at The H.C. Wainwright 23rd Annual Global Investment Conference
SALT LAKE CITY, Sept. 1, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the H.C. Wainwright 23rd Annual Global Investment Conference being
Read more →LPCNLipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study Histological Analysis Demonstrates Treatment Potential of LPCN 1144 in NASH Both LPCN 1144 treatment ar
LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study Analysis Demonstrates Treatment Potential of LPCN 1144 in NASH Both LPCN 1144 treatment arms met with statistical significance the pre-specified histology based regulatory
Read more →LPCNLipocine Announces Financial Results for the Second Quarter Ended June 30, 2021
SALT LAKE CITY, Aug. 5, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the second quarter ended June 30, 2021, and provided a corporate update. Rece
Read more →LPCNLipocine Announces Settlement With Clarus Therapeutics
Announces Settlement With Clarus Therapeutics LAKE CITY, July 14, 2021 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into a global settlement and license agreement wit
Read more →LPCNLipocine To Present At The Ladenburg Thalmann Healthcare Conference
SALT LAKE CITY, July 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference. The conference will b
Read more →LPCNLipocine Announces Presentations at The International Liver Congress 2021 Digital Event
Lipocine Announces Presentations at The International Liver Congress 2021 Digital Event SALT LAKE CITY, June 23, 2021-- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data wi
Read more →LPCNLipocine To Present At The Raymond James Human Health Innovation Conference
SALT LAKE CITY, June 16, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James Human Health Innovation Conference. The conferen
Read more →LPCNForward - Looking Statements This presentation contains forward - looking statements about Lipocine Inc . (the "Company") . These forward - looking statements are made pursuant to the safe harbor provisions of the Privat
Enabling Oral Drug Delivery to Improve Patient Compliance June 2021 CORPORATE PRESENTATION Exhibit 99.1 Forward - Looking Statements This presentation contains forward - looking statements about Lipocine Inc . (the "Company") . These forward - looking statements are made pursuan
Read more →LPCNFDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study SALT LAKE CITY, June 14, 2021 -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Admini
Read more →LPCNBackground and Aims: Non-alcoholic Steatohepatitis (NASH) is
Title Oral LPCN 1144 treatment significantly reduced liver fat and key liver injury markers in biopsy confirmed NASH subjects: Results of a Phase 2 randomized controlled study Category NAFLD: Therapy Submitter Dr. Kilyoung Kim Speaker Dr. Kilyoung Kim, Lipocine Inc, Product Devel
Read more →LPCNLipocine to Present at the Lytham Partners Summer 2021 Investor Conference
SALT LAKE CITY, June 7, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Lytham Partners Summer 2021 Investor Conference. The conference
Read more →LPCNSummary Judgment RULING in Patent Infringement Lawsuit
Judgment RULING in Patent Infringement Lawsuit SALT LAKE CITY, UT, May 26, 2021 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the United States District Court for the District of De
Read more →LPCNLipocine To Present At M Vest / Maxim Conference And At The Lytham Partners Conference
SALT LAKE CITY, March 11, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the M Vest LLC and Maxim Group LLC Emerging Growth Virtual Confer
Read more →LPCNLipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis
Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis LAKE CITY, March 4, 2021 -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic an
Read more →LPCNLipocine Announces Presentations on TLANDO at ENDO 2021 Conference
Lipocine Announces Presentations on TLANDO at ENDO 2021 Conference LAKE CITY, March 3, 2021-- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO wil
Read more →LPCNLipocine to Present at Two Upcoming Investor Conferences
SALT LAKE CITY, Feb. 26, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James 42nd Annual Institutional Investors Conference a
Read more →LPCNLIPOCINE CLOSES UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK SALT LAKE CITY (
UNDERWRITTEN PUBLIC OFFERING OF COMMON SALT LAKE CITY (January 28, 2021) - Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of an underwritten public offering of 16,428,571 shares
Read more →LPCNLipocine Closes Underwritten Public Offering Of Common Stock
SALT LAKE CITY, Jan. 28, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of an underwritten public offering of 16,428,571 shares of its common stock, offered at
Read more →LPCNLipocine Prices $25 Million Underwritten Public Offering Of Common Stock
SALT LAKE CITY, Jan. 26, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of an underwritten public offering of 14,285,714 shares of its common stock, offered at
Read more →LPCNLIPOCINE PRICES $25 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK SALT LAKE CITY (
LIPOCINE PRICES $25 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON SALT LAKE CITY (January 26, 2021) - Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of an underwritten public o
Read more →LPCNLipocine Announces Launch Of Public Offering Of Common Stock
SALT LAKE CITY, Jan. 25, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In
Read more →LPCNLIPOCINE ANNOUNCES LAUNCH OF PUBLIC OFFERING OF COMMON STOCK SALT LAKE CITY (
LIPOCINE ANNOUNCES LAUNCH OF PUBLIC OFFERING CITY (January 25, 2021) - Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it intends to offer shares of its common stock for sale in an under
Read more →LPCNLipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications
SALT LAKE CITY, Jan. 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office ("
Read more →LPCNLipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects Conference Call Scheduled for 8:30 a.m. ET today Both LPCN 1144 treatment arms met the primary endpo
Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects Conference Call Scheduled for 8:30 a.m. ET today SALT LAKE CITY, January 12, 2021 -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical compan
Read more →LPCNLipocine to Present at the H.C. Wainwright BioConnect 2021 Conference
SALT LAKE CITY, Jan. 4, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced that the Company will participate in the H.C. Wainwright BioConnect 2021 Conference, being held virtually
Read more →LPCNEnabling Oral Drug Delivery to Improve Patient Compliance January 2021 Corporate Presentation Exhibit 99.1
Enabling Oral Drug Delivery to Improve Patient Compliance January 2021 Corporate Presentation Exhibit 99.1 Forward - Looking Statements This presentation contains forward - looking statements about Lipocine Inc . (the "Company") . These forward - looking statements are made purs
Read more →LPCNLipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study
Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study LAKE CITY, December 30, 2020 -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is enrolling patients into an
Read more →LPCNLipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics
Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics LAKE CITY, December 29, 2020 -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge
Read more →LPCNLipocine Announces Tentative Approval of TLANDO™
SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted tentative approval to TLANDO, its ora
Read more →LPCNLipocine Announces Deletion of Unauthorized Changes to Company's Website
Deletion of Unauthorized Changes to Company's Website SALT LAKE CITY, December 8, 2020 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an independent contractor posted on Lipocine's w
Read more →LPCNLipocine Provides New Regulatory Update on TLANDO™
SALT LAKE CITY, Dec. 4, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that it is continuing to
Read more →LPCNLipocine Provides New Regulatory Update on
Lipocine Provides New Regulatory Update SALT LAKE CITY, December 4, 2020 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the
Read more →LPCNLipocine Announces Third Quarter 2020 Financial and Operational Results
Lipocine Announces Third Quarter 2020 Financial and Operational Results SALT LAKE CITY, November 10, 2020 -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the third
Read more →LPCNTLANDO , Oral Testosterone Replacement Therapy without Dose Titration Requirement in Hypogonadal Men Anthony DelConte, MD 1,2 ; Nachiappan Chidambaram, PhD 1 ; Kongnara Papangkorn,
TLANDO , Oral Testosterone Replacement Therapy without Dose Titration Requirement in Hypogonadal Men Anthony DelConte, MD 1,2 ; Nachiappan Chidambaram, PhD 1 ; Kongnara Papangkorn, PhD 1 ; Benjamin J. Bruno, PharmD, PhD 1 ; Kilyoung Kim, PhD 1 ; Mahesh V. Patel, PhD 1 1 Lipocine
Read more →LPCNLipocine Provides Regulatory Update on TLANDO™
SALT LAKE CITY, Nov. 6, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that it is working towar
Read more →LPCNLipocine Provides Regulatory Update on
Lipocine Provides Regulatory Update on SALT LAKE CITY, November 6, 2020 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the
Read more →LPCNLipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and NASH at The Liver Meeting Digital Experience
Lipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and NASH at The Liver Meeting Digital Experience SALT LAKE CITY, November 5, 2020 -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and
Read more →LPCNLipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America
SALT LAKE CITY, Oct. 14, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present results from studies suggesting that low testosterone levels may play an important
Read more →LPCNLPCN 1144 Treatment Potential Assessment in a High Fat Diet Induced Rabbit Model of Hepatic Fibrosis and NASH Kilyoung Kim , Nachiappan Chidambaram, Anthony DelConte, Paolo Comeglio, Sandra Filippi, Kiran Vangara, Joel F
LPCN 1144 Treatment Potential Assessment in a High Fat Diet Induced Rabbit Model of Hepatic Fibrosis and NASH Kilyoung Kim, Nachiappan Chidambaram, Anthony DelConte, Paolo Comeglio, Sandra Filippi, Kiran Vangara, Joel Frank, Kongnara Papangkorn, Benjamin J Bruno, Mahesh V Pate
Read more →LPCNTLANDO, Oral Testosterone Replacement Therapy without Dose Titration Requirement Introduction: Most marketed testosterone replacement therapy (TRT) products require multiple dose adjustment visits to achieve desired eugo
TLANDO, Oral Testosterone Replacement Therapy without Dose Titration Requirement Introduction: Most marketed testosterone replacement therapy (TRT) products require multiple dose adjustment visits to achieve desired eugonadal testosterone (T) levels. For the majority of patie
Read more →LPCNLipocine to Present at the H.C. Wainwright 4th Annual NASH Investor Conference
SALT LAKE CITY, Sept. 29, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, will provide an update on LPCN 1144, an oral product of bioidentical testosterone being evaluated for the treatmen
Read more →LPCNLipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study Phase 2 Clinical Study Investigating LPCN 1144 in Biopsy-Confirmed Non-Cirrhotic NASH Subjects
Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study Phase 2 Clinical Study Investigating LPCN 1144 in Biopsy-Confirmed Non-Cirrhotic NASH Subjects SALT LAKE CITY, September 21, 2020 -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical compa
Read more →LPCNLipocine to Participate in HC Wainwright Annual Global Investment Conference
SALT LAKE CITY, Sept. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it will provide a corporate update at the 22nd HC Wainwright Annual Global Investment Conferen
Read more →LPCNLipocine Provides Regulatory Update for
Lipocine Provides Regulatory Update for SALT LAKE CITY, August 28, 2020 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the
Read more →LPCNLipocine Provides Regulatory Update for TLANDO™
SALT LAKE CITY, Aug. 28, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that it needs additiona
Read more →LPCNLipocine Announces Second Quarter 2020 Financial and Operational Results
Second Quarter 2020 Financial and Operational Results SALT LAKE CITY, August 6, 2020 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the second quarter ended June 30,
Read more →LPCNLipocine Announces Publication of LPCN 1144 Liver Fat Study ("LFS") Results
Lipocine Announces Publication of LPCN 1144 Liver Fat Study ("LFS") Results SALT LAKE CITY, August 3, 2020 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the peer reviewed publication of
Read more →LPCNLipocine Announces Derivative Suit Was Dismissed
Derivative Suit Was Dismissed SALT LAKE CITY, July 31, 2020 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Wajda v. Patel, et al., Case: 2019-0122-JTL, a putative shareholder derivat
Read more →LPCNLipocine Regains Compliance With Nasdaq Minimum Bid Price Requirement
SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC ("Nasdaq") on July 9, 2020 indicatin
Read more →LPCNLipocine Announces Presentations on TLANDO at AUA Virtual Experience 2020
Lipocine Announces Presentations on TLANDO at AUA Virtual Experience 2020 SALT LAKE CITY, May 15, 2020 -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candida
Read more →LPCNTreatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model
Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model SALT LAKE CITY, May 13, 2020 -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of a pre-
Read more →LPCNEnabling Oral Drug Delivery to Improve Patient Compliance May 2020 Corporate Presentation Exhibit 99.1
Enabling Oral Drug Delivery to Improve Patient Compliance May 2020 Corporate Presentation Exhibit 99.1 Forward - Looking Statements This presentation contains forward - looking statements about Lipocine Inc . (the "Company") . These forward - looking statements are made pursuant
Read more →LPCNLipocine Announces First Quarter 2020 Financial and Operational Results
SALT LAKE CITY, May 7, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the first quarter ended March 31, 2020, and provided a corporate update. First
Read more →LPCNFDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial
FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial SALT LAKE CITY, May 5, 2020 -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food & Drug Administration ("FD
Read more →LPCNU.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition
Denies Clarus's Oral Testosterone Ester Citizen Petition SALT LAKE CITY, UT, April 17, 2020 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the United States Food and Drug Administrat
Read more →LPCNLipocine Announces US Court of Appeals for the Federal Circuit Affirms Decision of
Lipocine Announces US Court of Appeals for the Federal Circuit Affirms Decision of USPTO SALT LAKE CITY, UT, April 9, 2020 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that the U.S. Co
Read more →LPCNImpact of A New Oral Testosterone Undecanoate on Blood Pressure and Cardiovascular Risk Introduction: Chronic use of testosterone replacement therapy (TRT) might effect cardiovascular (CV) risk. Clinical trials for recen
Impact of A New Oral Testosterone Undecanoate on Blood Pressure and Cardiovascular Risk Introduction: Chronic use of testosterone replacement therapy (TRT) might effect cardiovascular (CV) risk. Clinical trials for recently approved TRTs have shown impacts on blood pressure (
Read more →LPCNLipocine Announces Outcome of Markman Hearing in Patent Infringement Suit Against Clarus
Lipocine Announces Outcome of Markman Hearing in Patent Infringement Suit Against Clarus SALT LAKE CITY, UT, March 26, 2020 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge Will
Read more →LPCNLipocine Announces 2019 Year End Financial and Operational Results
2019 Year End Financial and Operational Results SALT LAKE CITY, March 13, 2020 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019, and provided a corporate update. Fourth Quarter a
Read more →LPCNLipocine Announces TLANDO™ PDUFA Date of August 28, 2020
SALT LAKE CITY, March 4, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") acknowledged receipt of the resubmission of TLANDO New Drug Application ("NDA"), the Company'
Read more →LPCNLipocine Announces TLANDO PDUFA Date of
Announces TLANDO PDUFA Date of August 28, 2020 SALT LAKE CITY, March 4, 2020 -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") acknowledged receipt of the resubmission of TLANDO New D
Read more →LPCNLIPOCINE ANNOUNCES CLOSING OF REGISTERED DIRECT OFFERING OF COMMON STOCK AND WARRANTS SALT LAKE CITY (
LIPOCINE ANNOUNCES CLOSING OF REGISTERED DIRECT OFFERING OF COMMON STOCK AND WARRANTS (February 27, 2020) - Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a registered direct
Read more →LPCNLipocine Announces Closing Of Registered Direct Offering Of Common Stock And Warrants
SALT LAKE CITY, Feb. 27, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a registered direct offering of 10,084,034 Class A Units, each consisting of one shar
Read more →LPCNLIPOCINE ANNOUNCES $6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET SALT LAKE CITY (
LIPOCINE ANNOUNCES $6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET CITY (February 25, 2020) - Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into securities pu
Read more →LPCNLipocine Announces $6 Million Registered Direct Offering Priced At-The-Market
SALT LAKE CITY, Feb. 25, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into securities purchase agreements with certain institutional investors providi
Read more →LPCNLipocine Announces Regulatory Path Forward for TLANDO Resubmission
Lipocine Announces Regulatory Path Forward for TLANDO Resubmission SALT LAKE CITY, February 24, 2020 -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of its Post Action meeting with t
Read more →LPCNLipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics
Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics SALT LAKE CITY, February 11, 2020 -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that in an effort to streamline the issues and associated costs for dispute
Read more →LPCNA Novel Oral Testosterone Therapy (TLANDO) Safely Restores Testosterone To Eugonadal Levels With Fixed Dose Treatment Author Block: Anthony DelConte, MD1, Mahesh V. Patel, PhD2, Kongnara Papangkorn, PhD2, Nachiappan Chid
A Novel Oral Testosterone Therapy (TLANDO) Safely Restores Testosterone To Eugonadal Levels With Fixed Dose Treatment Author Block: Anthony DelConte, MD1, Mahesh V. Patel, PhD2, Kongnara Papangkorn, PhD2, Nachiappan Chidambaram, PhD2, Benjamin J. Bruno, PharmD, PhD2, Kilyoung
Read more →LPCNEnabling Oral Drug Delivery to Improve Patient Compliance January 2020 Corporate Presentation Exhibit 99.1
Enabling Oral Drug Delivery to Improve Patient Compliance January 2020 Corporate Presentation Exhibit 99.1 Forward - Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursua
Read more →LPCNLPCN 1144 (Oral Testosterone Undecanoate) Resolves Non-Alcoholic Fatty Liver Disease Michael Charlton 1 , Arun J. Sanyal 2 , Kilyoung kim 3 , Jonathan Baker 3 , Kongnara Papangkorn 3 , Nachiappan Chidambaram 3 , Mahesh V
LPCN 1144 (Oral Testosterone Undecanoate) Resolves Non-Alcoholic Fatty Liver Disease Michael Charlton1, Arun J. Sanyal2, Kilyoung kim3, Jonathan Baker3, Kongnara Papangkorn3, Nachiappan Chidambaram3, Mahesh V. Patel3, Somaya Albhaisi4 Hypogonadism, defined by low circulating
Read more →LPCNLIPOCINE ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS SALT LAKE CITY (
LIPOCINE ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS (November 18, 2019) - Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a public offering of (i) 10,450
Read more →LPCNLipocine Announces Closing Of Public Offering Of Common Stock And Warrants
SALT LAKE CITY, Nov. 18, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a public offering of (i) 10,450,000 Class A Units, each consisting of shares of its c
Read more →LPCNLipocine Announces Pricing Of Public Offering Of Common Stock And Warrants
SALT LAKE CITY, Nov. 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of a public offering of (i) 10,450,000 Class A Units, each consisting of shares of its
Read more →LPCNLIPOCINE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS SALT LAKE CITY (
LIPOCINE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON (November 14, 2019) - Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of a public offering of (i) 10,450,000 Class A Units,
Read more →LPCNLIPOCINE ANNOUNCES LAUNCH OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS SALT LAKE CITY (
LIPOCINE ANNOUNCES LAUNCH OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS (November 13, 2019) - Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the launch of a public offering of units consis
Read more →LPCNLipocine Announces Launch Of Public Offering Of Common Stock And Warrants
SALT LAKE CITY, Nov. 13, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the launch of a public offering of units consisting of shares of its common stock (or pre-funded war
Read more →LPCNLipocine Announces Third Quarter 2019 Financial and Operational Results
Third Quarter 2019 Financial and Operational Results LAKE CITY, November 12, 2019 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter and nine months ended September 30, 2019, and provided a corpora
Read more →LPCNLipocine Receives Complete Response Letter for TLANDO from
Lipocine Receives Complete Response Letter SALT LAKE CITY, November 11, 2019 -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United States Food and Drug Administration
Read more →LPCNLPCN 1144 Resolves Non Alcoholic Fatty Liver Disease INTRODUCTION R ESULTS - SOAR Hypogonadism, defined by low circulating testosterone (T) levels, is increasingly being recognized
LPCN 1144 Resolves Non Alcoholic Fatty Liver Disease INTRODUCTION R ESULTS - SOAR Hypogonadism, defined by low circulating testosterone (T) levels, is increasingly being recognized in those with metabolic syndrome, the principal risk factor for nonalcoholic fatty liver disease (N
Read more →LPCNConfidential 1 SMSNA 2019
1 Confidential 1 SMSNA 2019 October 25, 2019 LPCN Oral T (TLANDO) Reduces Liver Fat in Men with Fatty Liver Presenter: Irwin Goldstein, MD Director, Sexual Medicine, Alvarado Hospital, San Diego, CA Clinical Professor of Surgery, University of California at San Diego Authors: Irw
Read more →LPCNConfidential 1 SMSNA 2019 October 25, 2019 LPCN Oral T (TLANDO) Reduces Liver Fat in Men with Fat Liver Irwin Goldstein, MD University of California at San Diego Exhibit 99.1
1 Confidential 1 SMSNA 2019 October 25, 2019 LPCN Oral T (TLANDO) Reduces Liver Fat in Men with Fat Liver Irwin Goldstein, MD University of California at San Diego Exhibit 99.1 2 Confidential Low T is Associated with NAFLD Across the Disease Spectrum Kim et al., BMC Gastroentero
Read more →LPCNForward - Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions of the Private
Enabling Oral Drug Delivery to Improve Patient Compliance October 21, 2019 H.C. Wainwright 3 rd Annual NASH Investor Conference Exhibit 99.1 Forward - Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward -
Read more →LPCNLipocine to Present at the B. Riley NASH Symposium
SALT LAKE CITY, Oct. 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), clinical-stage biopharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will participate in a panel presentation at the B. Riley "NASH-ing in, Let's All Dig in on Wha
Read more →LPCNLipocine to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference
SALT LAKE CITY, Oct. 10, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), clinical-stage biopharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the H.C. Wainwright 3rd Annual NASH Investor Conference,
Read more →LPCNLPCN 1144 Resolves Non-Alcoholic Fatty Liver Disease Somaya Albhaisi 1 , Kilyoung kim 3 , Jonathan Baker 3 , Nachiappan Chidambaram 3 , Mahesh V. Patel 3 , Michael Charlton 4 , Arun J. Sanyal 2 1. Dept of Internal Medici
LPCN 1144 Resolves Non-Alcoholic Fatty Somaya Albhaisi1, Kilyoung kim3, Jonathan Baker3, Nachiappan Chidambaram3, Mahesh V. Patel3, Michael Charlton4, Arun 1. Dept of Internal Medicine, VCU, Richmond, 2. Div. of Gastroenterology, Hepatology and Nutrition, Dept. of Internal M
Read more →LPCNLipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019
SALT LAKE CITY, Oct. 1, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that data from a clinical trial of LPCN 1144 in non-alcoholic fatty liver disease ("NAFLD") will be
Read more →LPCNFIRST BIOPSY CONFIRMED NASH PATIENT DOSED IN LIPOCINE LIFT STUDY OF LPCN 1144
CONFIRMED NASH PATIENT DOSED IN LIPOCINE LIFT STUDY OF LPCN 1144 SALT LAKE CITY, September 30, 2019 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patient has been dosed in
Read more →LPCNTLANDO (LPCN 1144) Reduces Liver Fat in Men with Fatty Liver Irwin Goldstein 1 ; Kilyoung Kim 2 ; Somaya Albhaisa 3 ; Jonathan Baker 2 ; Nachiappan Chidambarum 2 ; Arun Sanyal 3 ; Mahesh V. Patel 2 ; Anthony DelConte 2,4
Reduces Liver Fat in Men with Fatty Liver Kilyoung Kim2; Somaya Albhaisa3; Jonathan Baker2; Nachiappan Chidambarum2; Arun Sanyal3; Mahesh V. Patel2; Anthony DelConte2,4 1: University of California at San Diego, San Diego, CA; 2: Lipocine Inc.; 3: Virginia Commonwealth Univers
Read more →LPCNLipocine Announces Presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America
SALT LAKE CITY, Sept. 23, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that four abstracts (two oral presentations and two posters) will be presented at the 20th Annual
Read more →LPCNLipocine to Present at the Ladenburg Thalmann 2019 Healthcare Conference
SALT LAKE CITY, Sept. 17, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Laden
Read more →LPCNLipocine to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma, Rare Disease & Gene Therapy
SALT LAKE CITY, Sept. 16, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will participate in the Oppenheimer & Co. Fall
Read more →LPCNLipocine Announces Trial Date in Lipocine's Infringement Lawsuit against Clarus Therapeutics and Will Seek a Permanent Injunction
Lipocine Announces Trial Date in Lipocine's Infringement Lawsuit against Clarus Therapeutics and Will Seek a Permanent Injunction SALT LAKE CITY, UT, August 27, 2019 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine
Read more →LPCNLipocine Withdraws Preliminary Injunction Threat Against Marketing of Clarus Therapeutics’ JATENZO Product: Trial Date Set for August 2020
NORTHBROOK, Ill., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Clarus today announced that Lipocine, Inc. has confirmed that it will not seek preliminary injunctive relief against Clarus in a lawsuit that asserts Clarus’s product JATENZO infringes certain Lipocine patents -- even in the eve
Read more →LPCNLipocine Announces Second Quarter 2019 Financial and Operational Results
Second Quarter 2019 Financial and Operational Results LAKE CITY, August 7, 2019 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the second quarter and six months ende
Read more →LPCNLipocine to Present at the Canaccord Genuity 39th Annual Growth Conference
SALT LAKE CITY, July 30, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Canacc
Read more →LPCNLipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population
Lipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population SALT LAKE CITY, UT, July 23, 2019 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today a
Read more →LPCNLipocine Set To Join Russell Microcap® Index
SALT LAKE CITY, Utah, June 25, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2019 Russell inde
Read more →LPCNLipocine Set To Join Russell Microcap Index
Lipocine Set To Join Russell Microcap SALT LAKE CITY, UT, June 25, 2019 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is set to join the Russell Microcap Index at the conclusion
Read more →LPCNLipocine Announces TLANDO NDA PDUFA Action Date of
Lipocine Announces TLANDO NDA PDUFA Action Date of November 9, 2019 SALT LAKE CITY, May 14, 2019 -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA"
Read more →LPCNLipocine Announces First Quarter 2019 Financial and Operational Results
First Quarter 2019 Financial and Operational Results SALT LAKE CITY, May 8, 2019 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2019, and provided a corporate update. First Quarter and Rece
Read more →LPCNLipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' Jatenzo for Testosterone Replacement Therapy
Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' Jatenzo for Testosterone Replacement Therapy SALT LAKE CITY, UT, April 3, 2019 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today
Read more →LPCNLipocine Announces ABPM Labeling Study Results Consistent with Recently Approved Testosterone Replacement Therapy
Lipocine Announces ABPM Labeling Study Results Consistent with Recently Approved Testosterone Replacement Therapy SALT LAKE CITY, UT, March 27, 2019 - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today a
Read more →LPCNLipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers
Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers SALT LAKE CITY, UT, March 26, 2019 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today accep
Read more →LPCNLipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference
SALT LAKE CITY, March 21, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview and LPCN 1144's therapeutic potential for non-alcoholic steatohep
Read more →LPCNLipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019
SALT LAKE CITY, March 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical results as part of ENDO 2019. The presentation will highlight the therapeutic potential of LPCN
Read more →LPCNLipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population
Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population LAKE CITY, UT, March 12, 2019 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on endocrine and metabolic disorders,
Read more →LPCNLipocine to Participate at the 31st Annual ROTH Conference
SALT LAKE CITY, March 11, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Morgan Brown, Executive Vice President and Chief Financial Officer, will provide a corporate overview to investors at the 31st Annual ROTH Confere
Read more →LPCNTherapeutic Potential of LPCN 1144 in NAFLD/NASH Background & Aims Male hypogonadism is an underappreciated comorbidity in non-alcoholic fatty liver disease (NAFLD)/ steatohepatitis (NASH). A significant overlap of comor
Therapeutic Potential of LPCN 1144 in NAFLD/NASH Male hypogonadism is an underappreciated comorbidity in non-alcoholic fatty liver disease (NAFLD)/ steatohepatitis (NASH). A significant overlap of comorbidities such as obesity, hypertension, hypertriglyceridemia, type 2 diabet
Read more →LPCNLipocine Announces Financial and Operational Results for the Year Ended
Announces Financial and Operational Results for the Year Ended December 31, 2018 SALT LAKE CITY, March 6, 2019 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the year ended December Fourth Quarter 2019 and Recent Corpo
Read more →LPCNLipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects
Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects SALT LAKE CITY, February 14, 2019 -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration
Read more →LPCNLipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects
Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects LAKE CITY, UT, January 23, 2019 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application ("IND") with the U.S. Food
Read more →LPCNLipocine's NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim Results
Lipocine's NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim Results SALT LAKE CITY, UT, January 17, 2019 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced approximately eight-week top-line interim results from a
Read more →LPCNUSPTO GRANTS PRIORITY MOTION TO LIPOCINE AND ENTERS JUDGMENT AGAINST CLARUS SALT LAKE CITY (
USPTO GRANTS PRIORITY MOTION TO LIPOCINE AND ENTERS JUDGMENT AGAINST CLARUS SALT LAKE CITY (January 14, 2019) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Tr
Read more →LPCNLipocine Announces Successful Ex Vivo Conversion Assessment of
Successful Ex Vivo Conversion Assessment of TLANDO SALT LAKE CITY, Utah - December 31, 2018 - Lipocine, Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced completion of a definitive phlebotomy study ("Phlebotomy Study") to assess the extent, if any, of c
Read more →LPCNLipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference SALT LAKE CITY, UT, December 21, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 r
Read more →LPCNLipocine Announces LPCN 1144 MRI-PDFF Clinical Results Selected for Presentation at Keystone Symposia on Integrated Pathways of Disease in NASH and
Lipocine Announces LPCN 1144 MRI-PDFF Clinical Results Selected for Presentation at Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD SALT LAKE CITY, UT, December 20, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today t
Read more →LPCNAuthor disclosures are on file at AASLD. This study was funded by Lipocine Inc. Contact info: Dr. Jonathan Baker, jb@lipocine.com or admin@lipocine.com RESULTS * LPCN 1144 Patients for ALT 40 U/L at BL (N=42); ALT mean B
Oral Testosterone (LPCN 1144) Undecanoate Normalizes Liver Function Measures and Serum Triglycerides in Subjects at Risk for Non - Alcoholic Fatty Liver Disease (NAFLD) INTRODUCTION RESULTS - Cont'd R ESULTS - Cont'd Clinical testosterone (T) deficiency is prevalent across the hi
Read more →LPCNLipocine Announces Financial and Operational Results for the Three and Nine Months Ended
Financial and Operational Results for the Three and Nine Months Ended September 30, 2018 SALT LAKE CITY, UT, November 7, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended September 30,
Read more →LPCNLipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for
Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH SALT LAKE CITY, UT, November 5, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the proof-of-conce
Read more →LPCNLipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for
Lipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for TLANDO SALT LAKE CITY, UT, November 1, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the ambulatory blood pressure ("A
Read more →LPCNLipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting 2018
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting 2018 LAKE CITY, UT, October 11, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 11
Read more →LPCNEnabling oral drug delivery to improve patient compliance October 2018 Corporate Presentation Exhibit 99.1
Enabling oral drug delivery to improve patient compliance October 2018 Corporate Presentation Exhibit 99.1 Forward - Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursua
Read more →LPCNLipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference
SALT LAKE CITY, Sept. 25, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference, being held
Read more →LPCNNon - Alcoholic Fatty Liver Disease (NAFLD) and Its Clinical Progression Fatty liver is a reversible condition wherein large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis LFTs: Liver
LPCN 1144 Oral Testosterone (T) Non Alcoholic Steatohepatitis (NASH) and NASH Cirrhosis Exhibit 99.1 Non - Alcoholic Fatty Liver Disease (NAFLD) and Its Clinical Progression Fatty liver is a reversible condition wherein large vacuoles of triglyceride fat accumulate in liver cell
Read more →LPCNLipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018
SALT LAKE CITY, Aug. 7, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2018. Second Quarter and Recent Corporate Highlights Received a Complete Response Letter
Read more →LPCNLipocine to Present at the Canaccord Genuity 38th Annual Growth Conference
SALT LAKE CITY, Aug. 2, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Canaccord Genuity 38th Annual Growth Conference, being held
Read more →LPCNLipocine Announces Dosing in Ambulatory Blood Pressure Study for
Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO SALT LAKE CITY, UT, June 7, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the dosing of the first subject in the ambulatory blood pressure ("ABPM") clinical stud
Read more →LPCNLipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration
Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration SALT LAKE CITY, UT, May 9, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the Un
Read more →LPCNLipocine Announces Financial and Operational Results for the First Quarter Ended
Financial and Operational Results for the First Quarter Ended March 31, 2018 SALT LAKE CITY, UT, May 7, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2018. First Quarter and Rec
Read more →LPCNLipocine to Present at the 17th Annual Needham Healthcare Conference
SALT LAKE CITY, March 21, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the 17th Annual Needham Healthcare Conference, taking place Ma
Read more →LPCNLipocine Announces Settlement of Securities Class Action Lawsuit
Lipocine Announces Settlement of Securities Class Action Lawsuit SALT LAKE CITY, UT, February 16, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that the Company and the other defendants have entered into a memorandum of understanding
Read more →LPCNLipocine Announces $10 Million Loan and Security Agreement with Silicon Valley Bank
Lipocine Announces $10 Million Loan and Security Agreement with Silicon Valley Bank SALT LAKE CITY, UT, February 8, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced the receipt of $10.0 million in January 2018 by means of a Loan and Security
Read more →LPCNLipocine to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
SALT LAKE CITY, Feb. 7, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the LEERINK Partners 7th Annual Global Healthcare Conference, be
Read more →LPCNLipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO , Testosterone Replacement Therapy in Adult Males with Hypogonadism
Outcome of FDA Advisory Committee Meeting for TLANDO , Testosterone Replacement Therapy in Adult Males with Hypogonadism SALT LAKE CITY, UT, January 10, 2018 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Uro
Read more →LPCNLipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO™, Testosterone Replacement Therapy in Adult Males with Hypogonadism
SALT LAKE CITY, Utah, Jan. 10, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Urologic Drugs Advisory Committee ("BRUDAC") of the U.S. Food and Drug Administration ("FDA") voted six in favor a
Read more →LPCNU.S. FDA Extends Review for TLANDO™; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged
Lipocine Inc. announced that the FDA has extended the review period for TLANDO's NDA to May 8, 2018, to allow for additional data analysis. The previously scheduled advisory committee meeting on January 10, 2018, remains unchanged. The company emphasizes TLANDO's potential to meet the needs of men with hypogonadism.
Read more →LPCNU.S. FDA Extends Review for TLANDO ; Advisory Committee Meeting Date of
U.S. FDA Extends Review for TLANDO ; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged SALT LAKE CITY, UT, November 17, 2017 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") h
Read more →LPCNLipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017
SALT LAKE CITY, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended September 30, 2017. Third Quarter and Recent Corporate Highlights Resubmitted a New Drug Appl
Read more →LPCNLipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended
Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017 SALT LAKE CITY, UT, November 8, 2017 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended Septe
Read more →LPCNof Oral Testosterone Replacement Therapy (LPCN 1021): Analysis] of Two Fixed-Dose Regimens Exhibit 99.1 Marc Gittelman,1 Nachiappan
of Oral Testosterone Replacement Therapy (LPCN 1021): Analysis] of Two Fixed-Dose Regimens Exhibit 99.1 Marc Gittelman,1 Nachiappan Chidambaram,2 Anthony DelConte,2 Satish Nachaegari,2 Chris Welsh,2 Mahesh Patel,2 Jed Kaminetsky3 1 South Florida Medical Research, Aventura, FL;
Read more →LPCNFDA Advisory Committee Scheduled to Review TLANDO on
FDA Advisory Committee Scheduled to Review TLANDO on January 10, 2018 SALT LAKE CITY, UT, October 18, 2017 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has scheduled the Bone, Reproductive an
Read more →LPCNEnabling oral drug delivery to improve patient compliance September 26, 2017 Ladenburg Thalmann 2017 Healthcare Conference Exhibit 99.1
Enabling oral drug delivery to improve patient compliance September 26, 2017 Ladenburg Thalmann 2017 Healthcare Conference Exhibit 99.1 Forward - Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looki
Read more →LPCNLipocine Announces Motions Decision by USPTO in Interference Against Clarus
Lipocine Inc. announced that the USPTO's PTAB issued a decision in its patent interference case with Clarus Therapeutics. The PTAB granted Lipocine's motion to deny Clarus's original priority date, while also adjusting Lipocine's own priority date. This decision positions Clarus as the senior party, impacting the validity of its patent. A conference call is scheduled to discuss further steps.
Read more →LPCNLIPOCINE ANNOUNCES MOTIONS DECISION BY USPTO IN INTERFERENCE AGAINST CLARUS SALT LAKE CITY (
LIPOCINE ANNOUNCES MOTIONS DECISION BY USPTO IN INTERFERENCE AGAINST CLARUS SALT LAKE CITY (September 21, 2017) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that the Patent Trial and Appeal Board ("PTAB") of the United States Patent and
Read more →LPCNLipocine Announces FDA Advisory Committee Meeting for TLANDO™
Lipocine Inc. announced that the FDA's BRUDAC will discuss its NDA for TLANDO, an oral testosterone product for testosterone replacement therapy in men with hypogonadism. The meeting is expected before the PDUFA goal date of February 8, 2018. Lipocine is optimistic about TLANDO's potential, citing its efficacy and safety profile.
Read more →LPCNLipocine Announces FDA Advisory Committee Meeting for
Lipocine Announces FDA Advisory Committee SALT LAKE CITY, UT, September 20, 2017 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Urologic Drugs Advisory Committee ("BRUDAC") of the U.S. Food and Drug Administr
Read more →LPCNLipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Lipocine Inc. announced that Dr. Mahesh Patel, its CEO, will present a corporate overview at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017. The company is focused on developing innovative pharmaceutical products for men's and women's health. Lipocine's pipeline includes TLANDO, LPCN 1111, and LPCN 1107, with TLANDO currently under FDA review.
Read more →LPCNLipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Lipocine Inc. will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference. The event is scheduled for September 11-13, 2017, in New York City. Lipocine is advancing its pipeline, including TLANDO, which is under FDA review, and LPCN 1111, currently in Phase 2 testing.
Read more →LPCNLipocine Announces FDA Acknowledgement of TLANDO™ (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018
Lipocine Inc. announced that the FDA has acknowledged its NDA resubmission for TLANDO, an oral testosterone product for treating hypogonadism. The FDA deemed the resubmission a complete response to a previous letter and set a PDUFA goal date of February 8, 2018. TLANDO has shown efficacy in clinical trials and was well tolerated without serious adverse events.
Read more →LPCNLipocine Announces FDA Acknowledgement of TLANDO ("LPCN 1021") NDA Resubmission; PDUFA Goal Date
Announces FDA Acknowledgement of TLANDO ("LPCN 1021") NDA Resubmission; PDUFA Goal Date, February SALT LAKE CITY, UT, August 14, 2017 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration ("FDA") has acknow
Read more →LPCNLipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism
Lipocine Inc. has resubmitted its New Drug Application for LPCN 1021, an oral testosterone product for treating hypogonadism. This follows a Complete Response Letter from the FDA in June 2016, which highlighted dosing algorithm deficiencies. The company completed a dosing validation study to address these issues and expects a six-month review period from the FDA.
Read more →LPCNLipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017
Lipocine Inc. reported its financial results for Q2 and the first half of 2017, highlighting positive outcomes from dosing studies for LPCN 1021 and the submission of a Special Protocol Assessment request to the FDA for LPCN 1107. The company also initiated a preclinical study for LPCN 1111. Despite a net loss of $6.1 million in Q2, Lipocine remains optimistic about its product development pipeline.
Read more →LPCNLipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended
Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017 SALT LAKE CITY, UT, August 7, 2017 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 201
Read more →LPCNLipocine to Present at the Canaccord Genuity 37th Annual Growth Conference
SALT LAKE CITY, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Canaccord Genuity 37th Annual Growth Conference, being h
Read more →LPCNLipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
SALT LAKE CITY, June 26, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has submitted a Special Protocol Assessment (“SPA”) request to the U.S. Food and Drug Administration (“FDA”), as part of the ongoing interact
Read more →LPCNLipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth SALT LAKE CITY (
Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth SALT LAKE CITY (June 26, 2017) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that it has submitted a Special Protocol Assessment ("S
Read more →LPCNLipocine Validates “No Titration” Dosing Regimen With Positive Topline Efficacy Results for LPCN 1021, Oral Testosterone Candidate
LPCN 1021 achieved primary endpoints confirming the efficacy of twice daily oral administration LPCN 1021 generally met the pre-specified per dose secondary endpoints for twice daily oral administration New Drug Application resubmission planned in the third quarter of 2017 SAL
Read more →LPCNLipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation and Dosing Flexibility Studies of LPCN 1021
SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Company will host a conference call and webcast today, June 19, 2017 at 5:00 p.m. Eastern time to discuss top-line results from its Dosing V
Read more →LPCNLIPOCINE VALIDATES "NO TITRATION" DOSING REGIMEN WITH POSITIVE TOPLINE EFFICACY RESULTS FOR LPCN 1021, ORAL TESTOSTERONE CANDIDATE LPCN 1021 achieved primary endpoints confirming the efficacy of twi
LIPOCINE VALIDATES "NO TITRATION" DOSING REGIMEN WITH POSITIVE TOPLINE EFFICACY RESULTS FOR LPCN 1021, ORAL TESTOSTERONE CANDIDATE SALT LAKE CITY (June 19, 2017) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced results from both the Dosing Va
Read more →LPCNLipocine to Present at the Jefferies 2017 Healthcare Conference
SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, and Morgan Brown, Executive Vice President and CFO, will provide a corporate overview at the Jeff
Read more →LPCNLipocine Announces Financial and Operational Results for the First Quarter 2017
SALT LAKE CITY, May 08, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2017. First Quarter and Recent Corporate Highlights • Announced completion of enrollment in
Read more →LPCNLipocine Completes Enrollment in the LPCN 1021 Fixed Dose Clinical Trials
Top-line data from the studies expected in June 2017 SALT LAKE CITY, April 24, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the completion of enrollment for both its dosing validation ("DV") study and its dosing flexib
Read more →LPCNLIPOCINE COMPLETES ENROLLMENT IN THE LPCN 1021 FIXED DOSE CLINICAL TRIALS Top-line data from the studies expected in June 2017 SALT LAKE CITY (
LIPOCINE COMPLETES ENROLLMENT IN THE LPCN 1021 FIXED DOSE CLINICAL TRIALS SALT LAKE CITY (April 24, 2017) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the completion of enrollment for both its dosing validation ("DV") study and its dosin
Read more →LPCNForward Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions of the Private Se
16 th Annual Needham Healthcare Conference April 4, 2017 Exhibit 99.1 Forward Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions of the
Read more →LPCNLipocine to Present at 16th Annual Needham Healthcare Conference
SALT LAKE CITY, March 28, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 16th Annual Needham
Read more →LPCNLipocine to Present at 27th Annual Oppenheimer Conference
SALT LAKE CITY, March 14, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 27th Annual Oppenhe
Read more →LPCNth Annual Roth Conference
29 th Annual Roth Conference March 13, 2017 Forward Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions of the Private Securities Litiga
Read more →LPCNLIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FULL YEAR OF 2016 SALT LAKE CITY (
LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FULL YEAR OF 2016 SALT LAKE CITY (March 6, 2017) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial and operational results for the full year ended December 31, 2016. "Dur
Read more →LPCNLipocine Announces Financial and Operational Results for the Full Year of 2016
SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the full year ended December 31, 2016. Initiated both a Dosing Validation (“DV”) Study and a Dosing Flexibili
Read more →LPCNLipocine to Present at 29th Annual ROTH Conference
SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 29th Annual ROTH Co
Read more →LPCNLIPOCINE ANNOUNCES THE PROMOTION OF GREGORY BASS TO CHIEF COMMERCIAL OFFICER SALT LAKE CITY (
LIPOCINE ANNOUNCES THE PROMOTION OF GREGORY BASS TO CHIEF COMMERCIAL OFFICER SALT LAKE CITY (February 15, 2017) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on developing innovative oral treatment alternatives for use in men's and women's health,
Read more →LPCNLipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer
SALT LAKE CITY, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company focused on developing innovative oral treatment alternatives for use in men’s and women’s health, today announced the promotion of Gregory Bass to the newly created p
Read more →LPCNLIPOCINE RECEIVES FDA GUIDANCE ON THE PHASE 3 PROGRAM FOR LPCN 1107, AN ORAL ALTERNATIVE FOR THE PREVENTION OF PRETERM BIRTH Critical Phase 3 study design input received from U.S. Food and Drug Admi
LIPOCINE RECEIVES FDA GUIDANCE ON THE PHASE 3 PROGRAM FOR LPCN 1107, AN ORAL ALTERNATIVE FOR THE PREVENTION OF PRETERM BIRTH SALT LAKE CITY (January 9, 2017) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced receipt of additional guidance from
Read more →LPCNLipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
Critical Phase 3 study design input received from U.S. Food and Drug Administration (“FDA”): Agreed to a randomized open-label, two-arm clinical study to include a LPCN 1107 arm and a comparator intramuscular (“IM”) arm with treatment up to 23 weeks Provided positive feedback on
Read more →LPCNLipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate
SALT LAKE CITY, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced plans to initiate a dosing flexibility (“DF”) study in addition to its previously announced dosing validation (“DV”) study for LPCN 1021. LPCN 1021 i
Read more →LPCNLIPOCINE INITIATES A DOSING FLEXIBILITY STUDY FOR LPCN 1021, ITS ORAL TESTOSTERONE REPLACEMENT PRODUCT CANDIDATE SALT LAKE CITY (
LIPOCINE INITIATES A DOSING FLEXIBILITY STUDY FOR LPCN 1021, ITS ORAL TESTOSTERONE REPLACEMENT PRODUCT CANDIDATE SALT LAKE CITY (January 5, 2017) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced plans to initiate a dosing flexibility ("DF")
Read more →LPCNLipocine to Initiate Dosing Validation Study for LPCN 1021, Oral Testosterone Replacement Product Candidate
SALT LAKE CITY, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced it plans to initiate a dosing validation study after receiving feedback from the U.S. Food and Drug Administration (“FDA”) of its protocol for LPCN 1
Read more →LPCNLIPOCINE TO INITIATE DOSING VALIDATION STUDY FOR LPCN 1021, ORAL TESTOSTERONE REPLACEMENT PRODUCT CANDIDATE SALT LAKE CITY (DECEMBER 5, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutic
LIPOCINE TO INITIATE DOSING VALIDATION STUDY FOR LPCN 1021, ORAL TESTOSTERONE REPLACEMENT PRODUCT CANDIDATE SALT LAKE CITY (DECEMBER 5, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced it plans to initiate a dosing validation study afte
Read more →LPCNLipocine Announces Financial and Operational Results for the Third Quarter of 2016
SALT LAKE CITY, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended September 30, 2016. Quarterly and Recent Highlights Completed a Post Action meeting with th
Read more →LPCNLIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE THIRD QUARTER OF 2016 SALT LAKE CITY (NOVEMBER 8, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announc
LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE THIRD QUARTER OF 2016 SALT LAKE CITY (NOVEMBER 8, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended Quarterly and Recen
Read more →LPCNLipocine Announces Issuance of US Patent 9,480,690
SALT LAKE CITY, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today reported the United States Patent and Trademark Office (“USPTO”) issued U.S. Patent number 9,480,690, entitled “High-Strength Testosterone Undecanoate Composit
Read more →LPCNLIPOCINE ANNOUNCES ISSUANCE OF US PATENT 9,480,690 SALT LAKE CITY (
LIPOCINE ANNOUNCES ISSUANCE OF US PATENT SALT LAKE CITY (November 7, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today reported the United States Patent and Trademark Office ("USPTO") issued U.S. Patent number 9,480,690, entitled "High-Strength Te
Read more →LPCNLipocine Completes Post Action Meeting With FDA for LPCN 1021 New Drug Application
SALT LAKE CITY, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the completion of a Post Action meeting with the U.S. Food and Drug Administration (“FDA”) regarding its New Drug Application (“NDA”) for LPCN 1021,
Read more →LPCNLIPOCINE COMPLETES POST ACTION MEETING
LIPOCINE COMPLETES POST ACTION MEETING WITH FDA FOR THE LPCN 1021 NEW DRUG APPLICATION SALT LAKE CITY (OCTOBER 17, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the completion of a Post Action meeting with the U.S. Food and Drug Adm
Read more →LPCNLipocine Wins Dismissal of Patent Infringement Lawsuit Related to LPCN 1021
SALT LAKE CITY, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that U.S. District Court in Delaware granted our motion to dismiss a lawsuit filed by Clarus Therapeutics, Inc. (“Clarus”). Clarus claimed that LPCN
Read more →LPCNLIPOCINE WINS DISMISSAL OF PATENT INFRINGEMENT LAWSUIT RELATED TO LPCN 1021 SALT LAKE CITY (
LIPOCINE WINS DISMISSAL OF PATENT INFRINGEMENT LAWSUIT RELATED TO LPCN 1021 SALT LAKE CITY (October 7, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that U.S. District Court in Delaware granted our motion to dismiss a lawsuit filed
Read more →LPCNLipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy
Once-daily dose identified for the pivotal Phase 3 study Well tolerated with no drug-related severe or serious adverse events reported SALT LAKE CITY, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today reported positive top
Read more →LPCNLIPOCINE ANNOUNCES POSITIVE TOP-LINE PHASE 2B STUDY RESULTS FOR LPCN 1111, A NEXT GENERATION ORAL TESTOSTERONE REPLACEMENT THERAPY Once-daily dose identified for the pivotal Phase 3 study Well toler
LIPOCINE ANNOUNCES POSITIVE TOP-LINE PHASE 2B STUDY RESULTS FOR LPCN 1111, A NEXT GENERATION ORAL TESTOSTERONE REPLACEMENT THERAPY SALT LAKE CITY (September 26, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today reported positive top-line results f
Read more →LPCNLipocine to Present at 2016 Ladenburg Thalmann Healthcare Conference
SALT LAKE CITY, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 2016 Ladenburg Thal
Read more →LPCNForward Looking Statements 2 This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions of the Private
Annual Canaccord Genuity Growth Conference 2016 Presentation August 2016 Exhibit 99.1 Forward Looking Statements 2 This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor
Read more →LPCNLipocine Announces Financial and Operational Results for the Second Quarter of 2016
SALT LAKE CITY, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended June 30, 2016. Quarterly and Recent Highlights Received a Complete Response Letter ("CRL")
Read more →LPCNLIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE SECOND QUARTER OF 2016 SALT LAKE CITY (
LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE SECOND QUARTER OF 2016 SALT LAKE CITY (August 9, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended Quarterly and Recent
Read more →LPCNLipocine to Present at 36th Annual Canaccord Genuity Growth Conference
SALT LAKE CITY, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 36th Annual Canaccor
Read more →LPCNLipocine Receives Complete Response Letter (CRL) for LPCN 1021 From U.S. Food and Drug Administration
SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has received a Complete Response Letter (“CRL”) from the United States Food and Drug Administration (“FDA”) regarding its New Drug Applicatio
Read more →LPCNLIPOCINE RECEIVES COMPLETE RESPONSE LETTER (CRL) FOR LPCN 1021 FROM U.S. FOOD AND DRUG ADMINISTRATION SALT LAKE CITY (
LIPOCINE RECEIVES COMPLETE RESPONSE LETTER (CRL) FOR LPCN 1021 FROM U.S. FOOD AND DRUG ADMINISTRATION SALT LAKE CITY (June 29, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that it has received a Complete Response Letter ("CRL") fro
Read more →LPCNLIPOCINE ADDED TO RUSSELL 3000 AND RUSSELL GLOBAL INDEXES SALT LAKE CITY (
LIPOCINE ADDED TO RUSSELL 3000 AND RUSSELL GLOBAL INDEXES SALT LAKE CITY (June 27, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that it has been added to the Russell 3000 and Russell Global Indexes, effective after the U.S. market
Read more →LPCNLipocine Added to Russell 3000 and Russell Global Indexes
SALT LAKE CITY, June 27, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has been added to the Russell 3000® and Russell Global® Indexes, effective after the U.S. market opens on Monday June 27, 2016. Annual recon
Read more →LPCN] HYPOGONADAL MEN WITH DIABETES BENEFIT FROM LPCN 1021 (ORAL TESTOSTERONE) Christina Wang, MD 1 , Jed C.
] HYPOGONADAL MEN WITH DIABETES BENEFIT FROM LPCN 1021 (ORAL TESTOSTERONE) Christina Wang, MD 1 , Jed C. Kaminetsky, MD 2 , Martin M. Miner, MD 3 , Adrian S Dobs, MD, MHS 4 , Anthony DelConte, MD 5,6 Nachiappan Chidambaram 6 , Satish Nachaegari 6 , Mahesh Patel 6 , Mohit Khera, M
Read more →LPCNLong - term Safety and Tolerability of Oral Testosterone (LPCN 1021) in Hypogonadal Men: Results from the 52 - Week Phase 3 Study Mohit Khera, MD 1 , Christina Wang, MD 2 , Jed C.
Long - term Safety and Tolerability of Oral Testosterone (LPCN 1021) in Hypogonadal Men: Results from the 52 - Week Phase 3 Study Mohit Khera, MD 1 , Christina Wang, MD 2 , Jed C. Kaminetsky, MD 3 , Martin M. Miner, MD 4 , Adrian S Dobs, MD, MHS 5 , Nachiappan Chidambaram 6 , Ant
Read more →LPCNLIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FIRST QUARTER OF 2016 SALT LAKE CITY (
LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FIRST QUARTER OF 2016 SALT LAKE CITY (May 9, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended Quarterly and Recent Hig
Read more →LPCNLipocine Announces Financial and Operational Results for the First Quarter of 2016
SALT LAKE CITY, May 09, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended March 31, 2016. Quarterly and Recent Highlights Continued regulatory and pre-commercializati
Read more →LPCNLipocine Announces the Presentation of Clinical Data for Oral Testosterone Replacement Therapy Product Candidate TLANDO™ (“LPCN 1021”) at the 2016 American Urological Association Annual Meeting
SALT LAKE CITY, May 02, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for lead candidate TLANDO™ (“LPCN 1021”), will be presented in poster and podium presentations at the 2016 American Urological Asso
Read more →LPCNLIPOCINE ANNOUNCES THE PRESENTATION OF CLINICAL DATA FOR ORAL TESTOSTERONE REPLACEMENT THERAPY PRODUCT CANDIDATE TLANDO ("LPCN 1021") AT THE 2016 AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING SALT
LIPOCINE ANNOUNCES THE PRESENTATION OF CLINICAL DATA FOR ORAL TESTOSTERONE REPLACEMENT THERAPY PRODUCT CANDIDATE TLANDO ("LPCN 1021") AT THE 2016 AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING SALT LAKE CITY (May 2, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceut
Read more →LPCNCorporate Presentation April 2016 Exhibit 99.1
Corporate Presentation April 2016 Exhibit 99.1 Forward Looking Statements 2 This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions of the Private Securities L
Read more →LPCNLipocine to Present at 15th Annual Needham & Company Healthcare Conference
SALT LAKE CITY, April 06, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at Needham & Company’s 15t
Read more →LPCNSubjects with the following pre - existing cardiovascular conditions reported in medical history at screening were classified as "CVD at baseline" for analysis Atrioventricular or
Subjects with the following pre - existing cardiovascular conditions reported in medical history at screening were classified as "CVD at baseline" for analysis Atrioventricular or bundle branch block, arrhythmia, tachycardia, atrial fibrillation, sinus bradycardia, premature vent
Read more →LPCNHypogonadal Men with and without Cardiovascular Disorders Benefit from LPCN 1021 (Oral Testosterone) - SOAR (Study of Androgen Replacement) Trial Mohit Khera, MD 1 , Adrian S Dobs, MD, MHS 2 , Christina Wang, MD 3 , Jed
Hypogonadal Men with and without Cardiovascular Disorders Benefit from LPCN 1021 (Oral Testosterone) - SOAR (Study of Androgen Replacement) Trial Mohit Khera, MD1, Adrian S Dobs, MD, MHS2, Christina Wang, MD3, Jed C. Kaminetsky, MD4, Irwin Goldstein, MD5, Anthony DelConte, MD6
Read more →LPCNLipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at ENDO 2016
SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone replacement therapy ("TRT") product candidate being developed for adult males with conditions
Read more →LPCNLIPOCINE ANNOUNCES THE PRESENTATION OF CLINICAL DATA FOR LPCN 1021, ITS ORAL TESTOSTERONE REPLACEMENT THERAPY PRODUCT CANDIDATE, AT ENDO 2016 SALT LAKE CITY (
LIPOCINE ANNOUNCES THE PRESENTATION OF CLINICAL DATA FOR LPCN 1021, ITS ORAL TESTOSTERONE REPLACEMENT THERAPY PRODUCT CANDIDATE, AT ENDO 2016 SALT LAKE CITY (March 28, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that clinical data
Read more →LPCNLIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FULL YEAR OF 2015 SALT LAKE CITY (
LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FULL YEAR OF 2015 SALT LAKE CITY (March 10, 2016) - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December Quarterly and Recent Highlight
Read more →LPCNLipocine Announces Financial and Operational Results for the Full Year of 2015
SALT LAKE CITY, March 10, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2015. Quarterly and Recent Highlights Announced the acceptance of its 505(b)(2) New Drug Ap
Read more →LPCNLipocine to Present at 28th Annual Roth Conference
SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 28th Annual Roth Co
Read more →LPCNLipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women
Relevant hydroxyprogesterone caproate levels achieved following oral administration Amenable to dose adjustment while on therapy Well tolerated with no serious adverse events or adverse drug reactions SALT LAKE CITY, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN
Read more →LPCNLIPOCINE REPORTS POSITIVE RESULTS OF MULTI-DOSE PHARMACOKINETIC STUDY OF LPCN 1107 FOR THE PREVENTION OF PRETERM BIRTH IN PREGNANT WOMEN Relevant hydroxyprogesterone caproate levels achieved followi
LIPOCINE REPORTS POSITIVE RESULTS OF MULTI-DOSE PHARMACOKINETIC STUDY OF LPCN 1107 FOR THE PREVENTION OF PRETERM BIRTH IN SALT LAKE CITY (February 16, 2016) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced top-line results fr
Read more →LPCNFebruary 2016 Exhibit 99.1
February 2016 Exhibit 99.1 Forward Looking Statements 2 This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act
Read more →LPCNForward Looking Statements 2 This presentation contains forward - looking statements about Lipocine Inc.
January 2016 Exhibit 99.1 Forward Looking Statements 2 This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act
Read more →LPCNLIPOCINE ANNOUNCES FIRST PATIENT DOSED IN PHASE 2B CLINICAL STUDY FOR LPCN 1111, A NOVEL TESTOSTERONE REPLACEMENT THERAPY SALT LAKE CITY (
LIPOCINE ANNOUNCES FIRST PATIENT DOSED IN PHASE 2B CLINICAL STUDY FOR LPCN 1111, A NOVEL TESTOSTERONE REPLACEMENT THERAPY SALT LAKE CITY (January 4, 2016) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that the first patien
Read more →LPCNLipocine Announces First Patient Dosed in Phase 2B Clinical Study for LPCN 1111, a Novel Testosterone Replacement Therapy
SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Phase 2b clinical study for LPCN 1111, a novel testosterone replacement therapy ("TRT") product candidat
Read more →LPCNPiper Jaffray 2015 Healthcare Conference December 2015 Exhibit 99.1
Piper Jaffray 2015 Healthcare Conference December 2015 Exhibit 99.1 Forward Looking Statements 2 This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions of the
Read more →LPCNLipocine to Present at 27th Annual Piper Jaffray Healthcare Conference
SALT LAKE CITY, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 27th Annual Piper Ja
Read more →LPCNLIPOCINE ADOPTS STOCKHOLDER RIGHTS PLAN SALT LAKE CITY (
LIPOCINE ADOPTS STOCKHOLDER RIGHTS PLAN SALT LAKE CITY (November 13, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that on November 12, 2015 its board of directors adopted a stockholder rights plan designed to deter c
Read more →LPCNLipocine Adopts Stockholder Rights Plan
SALT LAKE CITY, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that on November 12, 2015 its board of directors adopted a stockholder rights plan designed to deter coercive takeover tactics, including the accumul
Read more →LPCNLipocine Announces PDUFA Goal Date for LPCN 1021 NDA
SALT LAKE CITY, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has assigned a Prescription Drug User Fee Act ("PDUFA") goal date of June 28, 2016 for completion
Read more →LPCNLipocine Announces Financial and Operational Results for the Third Quarter of 2015
SALT LAKE CITY, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2015, as well as recent operational highlights. Quarterly and Recent Highlights Submitted a 5
Read more →LPCNLIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE THIRD QUARTER OF 2015 SALT LAKE CITY (
LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE THIRD QUARTER OF 2015 SALT LAKE CITY (November 12, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2015
Read more →LPCNLIPOCINE ANNOUNCES PDUFA GOAL DATE FOR LPCN 1021 NDA SALT LAKE CITY (
LIPOCINE ANNOUNCES PDUFA GOAL DATE FOR SALT LAKE CITY (November 12, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has assigned a Prescription Drug User Fee Act ("PDUF
Read more →LPCNLipocine Announces Presentation of LPCN 1021 Clinical Data at 21st Annual SMSNA Meeting
SALT LAKE CITY, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions a
Read more →LPCNLIPOCINE ANNOUNCES PRESENTATION OF LPCN 1021 CLINICAL DATA AT 21st ANNUAL SMSNA MEETING SALT LAKE CITY (
LIPOCINE ANNOUNCES PRESENTATION OF LPCN 1021 CLINICAL DATA AT 21st ANNUAL SMSNA MEETING SALT LAKE CITY (November 11, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosteron
Read more →LPCNFDA ACCEPTS FOR FILING LIPOCINE'S NEW DRUG APPLICATION FOR ITS ORAL TESTOSTERONE REPLACEMENT PRODUCT CANDIDATE, LPCN 1021 SALT LAKE CITY (
FDA ACCEPTS FOR FILING LIPOCINE'S NEW DRUG APPLICATION FOR ITS ORAL TESTOSTERONE REPLACEMENT PRODUCT CANDIDATE, LPCN 1021 SALT LAKE CITY (October 29, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that the U.S. Food a
Read more →LPCNCorporate Presentation October 2015 Exhibit 99.1
Corporate Presentation October 2015 Exhibit 99.1 Lipocine Investment Highlights First oral testosterone replacement option - Targeting ~ $2.0 Billion TRT market - NDA submitted August 2015 - Differentiated from existing products Orphan designated oral alternative for the prevent
Read more →LPCNLIPOCINE ANNOUNCES FIRST SUBJECT DOSED IN MULTI-DOSE PK STUDY FOR ITS ORAL PRODUCT CANDIDATE FOR THE PREVENTION OF PRE-TERM BIRTH SALT LAKE CITY (
LIPOCINE ANNOUNCES FIRST SUBJECT DOSED IN MULTI-DOSE PK STUDY FOR ITS ORAL PRODUCT CANDIDATE FOR THE PREVENTION OF PRE-TERM BIRTH SALT LAKE CITY (September 28, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced the first
Read more →LPCNLipocine Announces First Subject Dosed in Multi-Dose PK Study for Its Oral Product Candidate for the Prevention of Pre-Term Birth
SALT LAKE CITY, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the first subject dosed in its multi-dose PK dose finding clinical study for LPCN 1107, the company's oral hydroxyprogesterone caproate ("HPC") prod
Read more →LPCNLipocine to Present at Ladenburg Thalmann 2015 Healthcare Conference
SALT LAKE CITY, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the Ladenburg Thalmann
Read more →LPCNLIPOCINE SUBMITS NEW DRUG APPLICATION TO FDA FOR ITS ORAL TESTOSTERONE REPLACEMENT PRODUCT CANDIDATE, LPCN 1021 SALT LAKE CITY (
LIPOCINE SUBMITS NEW DRUG APPLICATION TO FDA FOR ITS ORAL TESTOSTERONE REPLACEMENT PRODUCT CANDIDATE, LPCN 1021 SALT LAKE CITY (August 31, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that is has submitted a 505(b)
Read more →LPCNLipocine Submits New Drug Application to FDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021
SALT LAKE CITY, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for LPCN 1021, an oral testosterone p
Read more →LPCNClick to edit Master title style 2 Forward Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe
Click to edit Master title style Corporate Presentation September 2015 Exhibit 99.1 Click to edit Master title style 2 Forward Looking Statements This presentation contains forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are m
Read more →LPCNLIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE SECOND QUARTER OF 2015 SALT LAKE CITY (
LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE SECOND QUARTER OF 2015 SALT LAKE CITY (August 11, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2015, as
Read more →LPCNLipocine Announces Financial and Operational Results for the Second Quarter of 2015
SALT LAKE CITY, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2015, as well as recent operational highlights. Quarterly and Recent Highlights Delivered top-line
Read more →LPCNLipocine to Present at 35th Annual Canaccord Genuity Growth Conference
SALT LAKE CITY, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 35th Annual Canaccord
Read more →LPCNLIPOCINE'S oral testosterone WELL TOLERATED IN PHASE 3 STUDY LPCN 1021 was well tolerated during 52 weeks of dosing No reported hepatic, cardiac or drug-related serious adverse events ( " SAEs " ) O
testosterone WELL TOLERATED IN PHASE 3 STUDY LAKE CITY (June 29, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced top-line 52-week safety results from its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clini
Read more →LPCNLipocine's Oral Testosterone Well Tolerated in Phase 3 Study
LPCN 1021 was well tolerated during 52 weeks of dosing No reported hepatic, cardiac or drug-related serious adverse events ("SAEs") Overall adverse event ("AE") profile for LPCN 1021 was comparable to the active control, Androgel 1.62% SALT LAKE CITY, June 29, 2015 (GLOBE NEWS
Read more →LPCNLipocine to Present at the JMP Securities Life Sciences Conference
SALT LAKE CITY, June 16, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the JMP Securi
Read more →LPCNLIPOCINE ANNOUNCES SUCCESSFUL COMPLETION OF FOOD EFFECT STUDY FOR LPCN 1021, AN ORAL TESTOSTERONE PRODUCT CANDIDATE Consistent and predictable therapeutic levels of testosterone when administered wi
LIPOCINE ANNOUNCES SUCCESSFUL COMPLETION OF FOOD EFFECT STUDY FOR LPCN 1021, AN ORAL TESTOSTERONE PRODUCT CANDIDATE SALT LAKE CITY (June 15, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced the successful completion of
Read more →LPCNLipocine Announces Successful Completion of Food Effect Study for LPCN 1021, an Oral Testosterone Product Candidate
Consistent and predictable therapeutic levels of testosterone when administered with a meal No significant sensitivity to meal fat content SALT LAKE CITY, June 15, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the succ
Read more →LPCNLIPOCINE ANNOUNCES DEVELOPMENT PLANS FOR LPCN 1107 SALT LAKE CITY (
LIPOCINE ANNOUNCES DEVELOPMENT PLANS SALT LAKE CITY (June 8, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced its development plans for LPCN 1107, the company's oral hydroxyprogesterone caproate ("HPC") product candidate
Read more →LPCNLipocine Announces Development Plans for LPCN 1107
SALT LAKE CITY, June 8, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced its development plans for LPCN 1107, the company's oral hydroxyprogesterone caproate ("HPC") product candidate. Recently the company received a Type C
Read more →LPCNLIPOCINE RECEIVES FDA ORPHAN DRUG DESIGNATION FOR LPCN 1107, AN ORAL PRODUCT CANDIDATE FOR THE PREVENTION OF PRETERM BIRTH SALT LAKE CITY (
LIPOCINE RECEIVES FDA ORPHAN DRUG DESIGNATION FOR LPCN 1107, AN ORAL PRODUCT CANDIDATE FOR THE PREVENTION OF PRETERM BIRTH SALT LAKE CITY (June 2, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug A
Read more →LPCNLipocine Receives FDA Orphan Drug Designation for LPCN 1107, an Oral Product Candidate for the Prevention of Preterm Birth
SALT LAKE CITY, June 2, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation to LPCN 1107, the company's oral hydroxyprogesterone caproate ("HPC"
Read more →LPCNLIPOCINE APPOINTS DR. JYRKI MATTILA AS CHIEF BUSINESS OFFICER SALT LAKE CITY (
LIPOCINE APPOINTS DR. JYRKI MATTILA AS CHIEF BUSINESS OFFICER LAKE CITY (May 18, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced the appointment of Dr. Jyrki Mattila, M.D., Ph.D., M.B.A to the newly created position of
Read more →LPCNThis study was supported by Lipocine Inc. J. C. Kaminetsky - Research funding (Principal investigator): AbbVie , Antares, Auxilium , Clarus, Ferring , Lipocine; Consulting fees: Antares, Auxilium ; Contracted fee (Speake
Efficacy and Pharmacokinetics of LPCN 1021, a Novel Oral Testosterone Replacement Therapy, in Hypogonadal Men: Study of Androgen Replacement (SOAR) Jed C. Kaminetsky, MD 1 ; Anthony DelConte, MD 2,5 ; Srinivasan Venkateshwaran, PhD 2 ; Nachiappan Chidambaram, PhD 2 ; Satish Nacha
Read more →LPCNLipocine Appoints Dr. Jyrki Mattila as Chief Business Officer
SALT LAKE CITY, May 18, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the appointment of Jyrki Mattila, M.D., Ph.D., M.B.A to the newly created position of Executive Vice President and Chief Business Officer. In this rol
Read more →LPCNLipocine Announces Presentation of Additional LPCN 1021 Clinical Data at American Urological Association Annual Meeting
SALT LAKE CITY, May 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that additional data from its ongoing Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study (http://clinicaltrials.gov/show/NCT02
Read more →LPCNLIPOCINE ANNOUNCES PRESENTATION OF ADDITIONAL LPCN 1021 CLINICAL DATA AT AMERICAN UROLOGICAL ASSOCATION ANNUAL MEETING SALT LAKE CITY (
LIPOCINE ANNOUNCES PRESENTATION OF ADDITIONAL LPCN 1021 CLINICAL DATA AT AMERICAN UROLOGICAL ASSOCATION ANNUAL MEETING SALT LAKE CITY (May 11, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that additional data from i
Read more →LPCNLIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FIRST QUARTER OF 2015 SALT LAKE CITY (
LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FIRST QUARTER OF 2015 SALT LAKE CITY (May 7, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2015, as well
Read more →LPCNLipocine Announces Financial and Operational Results for the First Quarter of 2015
SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2015, as well as recent operational highlights. Quarterly and Recent Highlights Completed the last
Read more →LPCNLIPOCINE ANNOUNCES COMPLETION OF LPCN 1021, ORAL TESTOSTERONE, PHASE 3 CLINICAL TRIAL SALT LAKE CITY (
LIPOCINE ANNOUNCES COMPLETION OF LPCN 1021, ORAL TESTOSTERONE, PHASE 3 CLINICAL TRIAL SALT LAKE CITY (April 30, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that the completion of the last patient visit in the safet
Read more →LPCNLipocine Announces Completion of LPCN 1021, Oral Testosterone, Phase 3 Clinical Trial
SALT LAKE CITY, April 30, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the completion of the last patient visit in the safety assessment portion of its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinica
Read more →LPCNLIPOCINE ANNOUNCES CLOSING OF $34.8 MILLION COMMON STOCK OFFERING SALT LAKE CITY (
LIPOCINE ANNOUNCES CLOSING OF $34.8 MILLION COMMON STOCK OFFERING SALT LAKE CITY (April 29, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced the closing of an underwritten public offering of 5,347,500 shares of its comm
Read more →LPCNLipocine Prices $30.2 Million Public Offering of Common Stock
SALT LAKE CITY, April 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has priced an underwritten public offering of 4,650,000 shares of its common stock at $6.50 per share for gross proceeds of $30.2 million. L
Read more →LPCNLIPOCINE PRICES $30.2 MILLION PUBLIC OFFERING OF COMMON STOCK SALT LAKE CITY (
LIPOCINE PRICES $30.2 MILLION PUBLIC OFFERING OF COMMON STOCK SALT LAKE CITY (April 24, 2015) - Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has priced an underwritten public offering of 4,650,000 shares of its common stock at $6.50
Read more →LPCNLipocine Announces Proposed Public Offering of Common Stock
SALT LAKE CITY, April 23, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Lipocine expects to grant the underwriters a 30-day option t
Read more →LPCNLIPOCINE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK SALT LAKE CITY (
LIPOCINE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK SALT LAKE CITY (April 23, 2015) - Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Lipocine expe
Read more →LPCNLipocine Announces Presentation of Additional LPCN 1021 Clinical Data at American Society of Andrology 40th Annual Conference
SALT LAKE CITY, April 10, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced that additional data from its ongoing Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study (http://clinicaltrials.gov/show/NCT0
Read more →LPCNLIPOCINE ANNOUNCES PRESENTATION OF ADDITIONAL LPCN 1021 CLINICAL DATA AT AMERICAN SOCIETY OF ANDROLOGY 40 TH ANNUAL CONFERENCE SALT LAKE CITY (
LIPOCINE ANNOUNCES PRESENTATION OF ADDITIONAL LPCN 1021 CLINICAL DATA AT AMERICAN SOCIETY OF ANDROLOGY 40TH ANNUAL CONFERENCE SALT LAKE CITY (April 10, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that additional d
Read more →LPCNAdrian Dobs Research funding (Clinical researcher): Clarus, Endo; Honoraria (Advisory group): AbbVie , Endo, Lipocine , Inc. Anthony DelConte Consulting fees: Lipocine, Inc. Martin Miner Research funding (Clinical resear
Efficacy & Pharmacokinetics of LPCN 1021, Novel Oral TRT Obese & Non - Obese Hypogonadal Men Exhibit 99.1 Adrian Dobs Research funding (Clinical researcher): Clarus, Endo; Honoraria (Advisory group): AbbVie , Endo, Lipocine , Inc. Anthony DelConte Consulting fees: Lipocine, Inc.
Read more →LPCNLipocine Announces Results From Pre-NDA Meeting for LPCN 1021, an Oral Testosterone Product Candidate
SALT LAKE CITY, March 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has completed its pre-New Drug Application ("NDA") meeting with the U.S. Food and Drug Administration ("FDA") related to LPCN 1021, its Oral
Read more →LPCNLIPOCINE ANNOUNCES RESULTS FROM PRE-NDA MEETING FOR LPCN 1021, AN ORAL TESTOSTERONE PRODUCT CANDIDATE SALT LAKE CITY (
LIPOCINE ANNOUNCES RESULTS FROM PRE-NDA MEETING FOR LPCN 1021, AN ORAL TESTOSTERONE PRODUCT CANDIDATE SALT LAKE CITY (March 24, 2015) - Lipocine Inc. (NASDAQ Capital Market: LPCN), a specialty pharmaceutical company, today announced that it has completed its pre-New Drug App
Read more →LPCNLipocine Announces Financial and Operational Results for the Full Year 2014
SALT LAKE CITY, March 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2014, as well as recent operational highlights. Quarterly and Recent Highlights Lipocine pr
Read more →LPCNLipocine Announces Financial And Operational Results For The Full Year 2014 SALT LAKE CITY (
Lipocine Announces Financial And Operational Results For The Full Year 2014 SALT LAKE CITY (March 11, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2014, as well
Read more →LPCNThis study was supported by Lipocine Inc. CW - Research funding (Clinical researcher): Antares, Clarus, Lipocine, Prolor; Consulting fees: Clarus, Lipocine; Honoraria ( Advisory group ): TesoRx . AD - Consulting fees: Li
Efficacy and Pharmacokinetics of LPCN 1021, a Novel Oral Testosterone Replacement Therapy, in Hypogonadal Men: Study of Androgen Replacement (SOAR) Christina Wang, MD 1 ; Anthony DelConte, MD 2,5 ; Jed C. Kaminetsky, MD 3 ; Martin M. Miner, MD 4 ; Pavan Yadav, MD 1 ; Srinivasan V
Read more →LPCNThis presentation contains and our discussions during this conference may include forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor
Corporate Presentation March 2015 Exhibit 99.1 2 This presentation contains and our discussions during this conference may include forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisions
Read more →LPCNLipocine to Present at the 27th Annual ROTH Conference
SALT LAKE CITY, March 4, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 27th Annual ROTH Conferen
Read more →LPCNLIPOCINE ANNOUNCES PRESENTATION OF LPCN 1021 CLINICAL DATA AT ENDO 2015 SALT LAKE CITY (
LIPOCINE ANNOUNCES PRESENTATION OF LPCN 1021 CLINICAL DATA SALT LAKE CITY (February 27, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that data from its ongoing Study of Oral Androgen Replacement ("SOAR") pivotal Phas
Read more →LPCNLipocine Announces Presentation of LPCN 1021 Clinical Data at ENDO 2015
SALT LAKE CITY, Feb. 27, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from its ongoing Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study (http://clinicaltrials.gov/show/NCT02081300) ev
Read more →LPCNLipocine to Present at the Cowen and Company 35th Annual Health Care Conference
SALT LAKE CITY, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and Chief Executive Officer, and Morgan Brown, Executive Vice President and Chief Financial Officer, will present a comp
Read more →LPCNLipocine Announces Presentation of LPCN 1107 Clinical Data at the Society for Maternal-Fetal Medicine 35th Annual Meeting
SALT LAKE CITY, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from a successful Phase 1 study of LPCN 1107, the company's oral hydroxyprogesterone caproate ("HPC") product candidate will be presented a
Read more →LPCNLIPOCINE ANNOUNCES PRESENTATION OF LPCN 1107 CLINICAL DATA AT THE SOCIETY FOR MATERNAL-FETAL MEDICINE 35 th ANNUAL MEETING SALT LAKE CITY (
LIPOCINE ANNOUNCES PRESENTATION OF LPCN 1107 CLINICAL DATA AT THE SOCIETY FOR MATERNAL-FETAL MEDICINE 35th ANNUAL MEETING SALT LAKE CITY (January 30, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that data from a su
Read more →LPCNLipocine Inc. (Nasdaq: LPCN) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Jan. 16, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Mahesh Patel, Chairman, President and Chief Executive Officer will ring the Closing Bell. Na
Read more →LPCNLipocine Announces Positive Phase 1b Top-Line Results With LPCN 1107 in Pregnant Women
First demonstration of relevant hydroxyprogesterone caproate levels following oral administration in pregnant women Projected dose between 400 and 800 mg twice a day is expected to be comparable to marketed 250 mg weekly IM product Relative bioavailabilities similar between pre
Read more →LPCNLIPOCINE ANNOUNCES POSITIVE PHASE 1B TOP-LINE RESULTS WITH LPCN 1107 IN PREGNANT WOMEN First demonstration of relevant hydroxyprogesterone caproate levels following oral administration in pregnant w
LIPOCINE ANNOUNCES POSITIVE PHASE 1B TOP-LINE RESULTS WITH LPCN 1107 IN PREGNANT WOMEN SALT LAKE CITY (January 12, 2015) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced successful top-line results of a Phase 1b study of LPCN
Read more →LPCNFDA Confirms Lipocine's Previously-Agreed Clinical Development Plan For LPCN 1021 SALT LAKE CITY (
FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan For LPCN 1021 SALT LAKE CITY (December 15, 2014) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that it has received confirmation from the U.S. Food and Dr
Read more →LPCNCorporate Presentation December 2014 Exhibit 99.1
Corporate Presentation December 2014 Exhibit 99.1 2 This presentation contains and our discussions during this conference may include forward - looking statements about Lipocine Inc. (the "Company"). These forward - looking statements are made pursuant to the safe harbor provisi
Read more →LPCNLipocine to Present at the Piper Jaffray 26th Annual Healthcare Conference
SALT LAKE CITY, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the Piper Jaffray 26th Annual
Read more →LPCNLipocine Announces Management Changes
SALT LAKE CITY, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced changes to its executive management team. Changes include the departures of Dr. Srinivasan Venkateshwaran, Chief Technology Officer and Vice Presiden
Read more →LPCNLIPOCINE ANNOUNCES MANAGEMENT CHANGES SALT LAKE CITY (
LIPOCINE ANNOUNCES MANAGEMENT SALT LAKE CITY (November 17, 2014) - Lipocine Inc. (NASDAQ Capital Market: LPCN), a specialty pharmaceutical company, today announced changes to its executive management team. Changes include the departures of Dr. Srinivasan Venkateshwaran, Chief
Read more →LPCNLipocine Announces Financial and Operational Results for the Third Quarter of 2014 SALT LAKE CITY (
Lipocine Announces Financial and Operational Results for the Third Quarter of 2014 SALT LAKE CITY (November 10, 2014) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2014
Read more →LPCNLipocine Announces Financial and Operational Results for the Third Quarter of 2014
SALT LAKE CITY, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2014, as well as recent operational highlights. Quarterly and Recent Highlights LPCN 1021 dem
Read more →LPCNLIPOCINE ANNOUNCES POSITIVE TOP-LINE RESULTS IN PHASE 2A STUDY OF LPCN 1111 Candidate For Once Daily Dosing Single daily oral dose provides testosterone levels in the eugonadal range Demonstrated go
LIPOCINE ANNOUNCES POSITIVE TOP-LINE RESULTS IN PHASE 2A STUDY OF LPCN 1111 Candidate For Once Daily SALT LAKE CITY (October 13, 2014) - Lipocine Inc. (NASDAQ Capital Market: LPCN), a specialty pharmaceutical company, today announced positive top-line results from a Phase 2a
Read more →LPCNLipocine Announces Positive Top-Line Results in Phase 2a Study of LPCN 1111
Candidate For Once Daily Dosing Single daily oral dose provides testosterone levels in the eugonadal range Demonstrated good dose response Steady state achieved by day 14 No subject exceeded peak serum testosterone concentration of 1500 ng/dL on multi-dose exposure Consisten
Read more →LPCNLIPOCINE ANNOUNCES POSITIVE TOP-LINE RESULTS IN ITS PHASE 3 STUDY OF LPCN 1021 FOR ORAL TESTOSTERONE REPLACEMENT THERAPY Met primary efficacy endpoint by successfully restoring testosterone levels t
LIPOCINE ANNOUNCES POSITIVE TOP-LINE RESULTS IN ITS PHASE 3 STUDY OF LPCN 1021 FOR ORAL TESTOSTERONE REPLACEMENT THERAPY SALT LAKE CITY (September 24, 2014) - Lipocine Inc. (NASDAQ Capital Market: LPCN), a specialty pharmaceutical company, today announced positive top-line lin
Read more →LPCNLipocine Announces Positive Top-Line Results in Its Phase 3 Study of LPCN 1021 for Oral Testosterone Replacement Therapy
Met primary efficacy endpoint by successfully restoring testosterone levels to the normal range in 88% of the subjects Lower limit of the 95% confidence interval was 82% 85% of the subjects reached final dose with no more than one dose titration Majority of subjects ended on 2
Read more →LPCNLipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Phase 3 Study of LPCN 1021
SALT LAKE CITY, Sept. 23, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the Company will host a conference call and webcast tomorrow, September 24, 2014 at 8:45 a.m. Eastern time to discuss top-line results from its
Read more →LPCNLipocine Announces First Patient Dosed in Phase 1 Study in Pregnant Women of LPCN 1107, Potentially the First Oral Product for the Prevention of Preterm Birth SALT LAKE CITY (
Lipocine Announces First Patient Dosed in Phase 1 Study in Pregnant Women of LPCN 1107, Potentially the First Oral Product for the Prevention of Preterm Birth CITY (September 8, 2014) - Lipocine Inc. (NASDAQ Capital Market: LPCN), a specialty pharmaceutical company, today an
Read more →LPCNLipocine Announces First Patient Dosed in Phase 1 Study in Pregnant Women of LPCN 1107, Potentially the First Oral Product for the Prevention of Preterm Birth
SALT LAKE CITY, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the first patient was dosed in a Phase 1 study in pregnant women of LPCN 1107, the company's oral hydroxyprogesterone caproate (HPC) product candidat
Read more →LPCNLipocine Announces Financial and Operational Results for the Second Quarter of 2014 SALT LAKE CITY (
Lipocine Announces Financial and Operational Results for the Second Quarter of 2014 SALT LAKE CITY (August 13, 2014) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2014, as w
Read more →LPCNLipocine Announces Financial and Operational Results for the Second Quarter of 2014
SALT LAKE CITY, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2014, as well as recent operational highlights. Quarterly and Recent Highlights Lipocine completed
Read more →LPCNLipocine Announces Issuance of U.S. Patent for LPCN 1021 SALT LAKE CITY (
Lipocine Announces Issuance of U.S. Patent for LAKE CITY (July 15, 2014) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent number 8,778,922, enti
Read more →LPCNLipocine Announces Issuance of U.S. Patent for LPCN 1021
SALT LAKE CITY, July 15, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent number 8,778,922, entitled "Steroidal Compositions." This patent re
Read more →LPCNLipocine Added to Russell Microcap Index
SALT LAKE CITY, June 30, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it was added to the Russell Microcap Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indices on Jun
Read more →LPCNLipocine to Present at the Jefferies 2014 Global Healthcare Conference
SALT LAKE CITY, May 29, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the Jefferies
Read more →LPCNLipocine Announces First Patient Dosed in Phase 2a Study of LPCN 1111, A Novel Testosterone Ester for Oral Testosterone Replacement Therapy SALT LAKE CITY (
Lipocine Announces First Patient Dosed in Phase 2a Study of LPCN 1111, A Novel Testosterone Ester for Oral Testosterone Replacement Therapy SALT LAKE CITY (May 27, 2014) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that
Read more →LPCNLipocine Announces First Patient Dosed in Phase 2a Study of LPCN 1111, a Novel Testosterone Ester for Oral Testosterone Replacement Therapy
SALT LAKE CITY, May 27, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The prim
Read more →LPCNLipocine Announces Successful Phase 1 Results with LPCN 1107, Potentially the First Oral Product for the Prevention of Preterm Birth Significant absorption upon oral dosing of LPCN 1107 Good dose re
Lipocine Announces Successful Phase 1 Results with LPCN 1107, Potentially the First Oral Product for the Prevention of Preterm Birth SALT LAKE CITY (May 15, 2014) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced the success
Read more →LPCNLipocine Announces Successful Phase 1 Results With LPCN 1107, Potentially the First Oral Product for the Prevention of Preterm Birth
Significant absorption upon oral dosing of LPCN 1107 Good dose response demonstrated LPCN 1107 oral steady state 400mg BID exposure is about 55% of weekly 250mg IM product SALT LAKE CITY, May 15, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical
Read more →LPCNLipocine Announces Financial and Operational Results for the First Quarter of 2014
SALT LAKE CITY, May 13, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, announced today announced financial results for the quarter ended March 31, 2014, as well as recent operational highlights. Quarterly and Recent Highlights Complete
Read more →LPCNLipocine Announces Completion of Enrollment in its SOAR Phase 3 Study for Oral Testosterone Replacement Therapy - Top-line Efficacy Data Expected in 3Q14 - NDA filing expected in 2H15 SALT LAKE CITY
Lipocine Announces Completion of Enrollment in its SOAR Phase 3 Study for Oral Testosterone Replacement Therapy - Top-line Efficacy Data Expected in - NDA filing expected in 2H15 SALT LAKE CITY (April 29, 2014) - Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pha
Read more →LPCNLipocine Announces Completion of Enrollment in its SOAR Phase 3 Study for Oral Testosterone Replacement Therapy
- Top-line Efficacy Data Expected in 3Q14 - NDA filing expected in 2H15 SALT LAKE CITY, April 29, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the Company has completed enrollment of its Study of Oral Androgen Re
Read more →LPCNLipocine to Begin Trading on the NASDAQ Capital Market
SALT LAKE CITY, March 18, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation that its application to list the Company's common stock on the NASDAQ Capital Market has been approved by the NASDA
Read more →LPCNLipocine to Begin Trading on the NASDAQ Capital Market SALT LAKE CITY (
Lipocine to Begin Trading on the NASDAQ Capital Market SALT LAKE CITY (March 18, 2014) - Lipocine Inc. (OTCQB: LPCN), a specialty pharmaceutical company, today announced that it has received confirmation that its application to list the Company's common stock on the NASDAQ Ca
Read more →LPCNLipocine to Present at the 26th Annual ROTH Conference
SALT LAKE CITY, March 5, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 26th Annual ROTH Conferenc
Read more →LPCNLipocine Announces First Patient Dosed in Phase 3 Study for Oral Testosterone Replacement Therapy
SALT LAKE CITY, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study. The trial is designed to eval
Read more →LPCNLipocine Announces First Patient Dosed in Phase 3 Study for Oral Testosterone Replacement Therapy SALT LAKE CITY (
Lipocine Announces First Patient Dosed in Phase 3 Study for Oral Testosterone Replacement Therapy SALT LAKE CITY (February 10, 2014) - Lipocine Inc. (OTCQB: LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Study of Oral A
Read more →LPCNLipocine to Present at the 2014 Leerink Global Healthcare Conference
SALT LAKE CITY, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 2014 Leerink Global Healthc
Read more →LPCNLipocine Announces New Appointments to Its Board of Directors
SALT LAKE CITY, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced changes to the Company's Board of Directors, including the appointments of Dr. Stephen Hill, Mr. Jeffrey Fink, and Dr. R. Dana Ono, and th
Read more →LPCNLipocine Announces New Appointments to Its Board of Directors SALT LAKE CITY (
Lipocine Announces New Appointments to Its Board of Directors SALT LAKE CITY (January 7, 2014) - Lipocine Inc. (OTCQB/OTCBB: LPCN), a specialty pharmaceutical company, today announced changes to the Company's Board of Directors, including the appointments of Dr. Stephen Hill,
Read more →LPCNLipocine Chairman Receives Honorary Doctor of Science Degree From the University of Michigan
SALT LAKE CITY, Dec. 13, 2013 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced that Dr. William I. Higuchi will receive an honorary Doctor of Science degree from the University of Michigan at the winter commencement
Read more →LPCNLipocine Inc. Announces Exercise and Closing of Over-Allotment Option
SALT LAKE CITY, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the underwriters of its previously announced public offering have fully exercised their option to purchase an additional 223,800 shares of Lipocin
Read more →LPCNLipocine Inc. Announces Pricing of Public Offering of Common Stock
SALT LAKE CITY, Nov. 27, 2013 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced the pricing of an underwritten public offering of 1,492,000 shares of its common stock at a price to the public of $8.25 per share. The g
Read more →LPCNLIPOCINE INC. Condensed Balance Sheets (Unaudited)
Condensed Balance Sheets June 30, 2013 December 31, 2012 Assets Current assets: Cash and cash equivalents $ 3,606,499 $ 5,377,114 Accounts receivable 92,732 Prepaid and other current assets 123,317 90,934 Related-party receivable 3,815
Read more →LPCNLIPOCINE INC. Financial Statements
Financial Statements March 31, 2013 and 2012 Financial Statements March 31, 2013 and 2012 Page Financial Statements (Unaudited): Condensed Balance Sheets 1 Condensed Statements of Operations 2 Condensed Statements of Cash Flows 3 Notes to Condensed Financial S
Read more →Competitive Position
How LPCN ranks across every disease it competes inCompetitive Position is a premium feature
See how LPCN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial